var title_f21_11_21680="Water distribution systems for HD";
var content_f21_11_21680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Water distribution systems for hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of direct (right side) and indirect (left side) feed water distribution systems. In this example reverse osmosis is the last process in a purification cascade. With an indirect feed distribution system, product water from the reverse osmosis unit passes into a storage tank. A separate pump circulates water from the storage tank to the point of use (eg, dialysis stations). Water not used for dialysis is returned to the feed side of the reverse osmosis system (direct feed system) or the storage tank (indirect feed system), so that purified water flows in a continuously recirculating loop.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21680=[""].join("\n");
var outline_f21_11_21680=null;
var title_f21_11_21681="Apprehension relocation release tests for shoulder";
var content_f21_11_21681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82884/Appreh_relo_rel_tests_video.mp4?title=Apprehension+relocation+release+tests+for+shoulder\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apprehension, relocation, and release tests for the shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These tests work in combination and are most easily performed with the patient supine.&nbsp;For the apprehension test, the symptomatic arm is placed&nbsp;in the throwing position (shoulder abducted and externally rotated). Next, the clinician braces the posterior shoulder with one hand while using the other hand to push back on the wrist with steady pressure, thereby increasing the abduction and external rotation of the shoulder. Any sensation of impending dislocation at any time constitutes a positive test.&nbsp;The relocation&nbsp;immediately follows&nbsp;the apprehension test and is performed by simply reversing the forces being exerted by the examiner. Forced abduction and external rotation are stopped, and the clinician moves the hand that was bracing the posterior shoulder to the anterior shoulder. The examiner then pushes the humerus posteriorly. The resolution of either pain or the sensation of impending dislocation on the part of the patient represents a positive test.&nbsp;The release test is performed&nbsp;at the end of&nbsp;the relocation test when the clinician abruptly stops pushing the humerus posteriorly. Any sensation of impending dislocation on the part of the patient constitutes a positive test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21681=[""].join("\n");
var outline_f21_11_21681=null;
var title_f21_11_21682="Ascites cirrhosis CT";
var content_f21_11_21682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ascites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows a large volume of ascitic fluid surrounding a small shrunken cirrhotic liver. The fluid is of low attenuation and is free floating without septations or solid material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21682=[""].join("\n");
var outline_f21_11_21682=null;
var title_f21_11_21683="Azithromycin (ophthalmic): Drug information";
var content_f21_11_21683=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azithromycin (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13988?source=see_link\">",
"    see \"Azithromycin (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=see_link\">",
"    see \"Azithromycin (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7983203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AzaSite&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7983208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Macrolide;",
"     </li>",
"     <li>",
"      Antibiotic, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7983306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Bacterial conjunctivitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop into affected eye(s) twice daily (8-12 hours apart) for 2 days, then 1 drop into affected eye(s) once daily for 5 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7983305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=see_link\">",
"      see \"Azithromycin (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Bacterial conjunctivitis:",
"     </b>",
"     Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7983307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7983372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AzaSite&reg;: 1% (2.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7983206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7983312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     For ophthalmic use only; avoid touching tip of applicator to eye or other surfaces. Invert closed bottle and shake once before each use. With bottle inverted, remove cap, tilt head back and gently squeeze bottle to instill drop. Wash hands before and after instillation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7983223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial conjunctivitis caused by susceptible microorganisms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7983166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Azithromycin may be confused with azathioprine, erythromycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7983237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Ocular: Eye irritation (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal taste, blurred vision, contact dermatitis, corneal erosion, dry eyes, eye pain, facial edema, hives, nasal congestion, ocular reactions (burning, discharge, irritation, itching, stinging), periocular swelling, punctate keratitis, rash, sinusitis, urticaria, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7983233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azithromycin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7983234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, angioedema, and dermatologic reactions, have been reported with systemic use of azithromycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms, including fungi. Discontinue use and institute alternative therapy if superinfection is suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Solution contains benzalkonium chloride which may be absorbed by contact lenses; contact lens should not be worn during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical ophthalmic use only; do not inject subconjunctivally or introduce directly into the anterior chamber of the eye.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8043203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9800529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. The amount of azithromycin available systemically following topical application of the ophthalmic drops is estimated to be below quantifiable limits. Systemic absorption would be required in order for azithromycin to cross the placenta and reach the fetus. When administered orally or I.V., azithromycin crosses the placenta. Refer to the Azithromycin (Systemic) monograph for details.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8043264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9800532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of azithromycin available systemically following topical application of the ophthalmic drops is estimated to be below quantifiable limits. Systemic absorption would be required in order for azithromycin to enter breast milk. The manufacturer recommends that caution be exercised when administering azithromycin eye drops to nursing women. When administered orally or I.V., azithromycin enters breast milk. Refer to the Azithromycin (Systemic) monograph for details.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7983374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (AzaSite Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (2.5 mL): $108.95",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azyter (DE, FR, GB, HK, ID, IE, PT, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7983272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7983274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Systemic absorption estimated to be negligible",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8770 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21683=[""].join("\n");
var outline_f21_11_21683=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983208\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983306\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983305\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983307\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983372\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983206\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983312\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983223\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983166\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983237\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983233\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983234\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298804\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770050\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043203\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9800529\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8043264\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9800532\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983374\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276701\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983272\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983274\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13988?source=related_link\">",
"      Azithromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=related_link\">",
"      Azithromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=related_link\">",
"      Azithromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/51/33589?source=related_link\">",
"      Azithromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/3/6200?source=related_link\">",
"      Azithromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_11_21684="Intraoperative congenital diaphragmatic hernia";
var content_f21_11_21684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Intraoperative view of a congenital diaphragmatic hernia prior to primary repair in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Holly L Hedrick, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21684=[""].join("\n");
var outline_f21_11_21684=null;
var title_f21_11_21685="Clopidogrel: Patient drug information";
var content_f21_11_21685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clopidogrel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     see \"Clopidogrel: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=see_link\">",
"     see \"Clopidogrel: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Plavix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clopidogrel&reg;;",
"     </li>",
"     <li>",
"      CO Clopidogrel;",
"     </li>",
"     <li>",
"      Dom-Clopidogrel;",
"     </li>",
"     <li>",
"      Mylan-Clopidogrel;",
"     </li>",
"     <li>",
"      Plavix&reg;;",
"     </li>",
"     <li>",
"      PMS-Clopidogrel;",
"     </li>",
"     <li>",
"      RAN&trade;-Clopidogrel;",
"     </li>",
"     <li>",
"      Sandoz-Clopidogrel;",
"     </li>",
"     <li>",
"      Teva-Clopidogrel",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2719759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may not work as well in some people. A test can be done to see if you are one of these people. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stent patients: Talk with your heart doctor before stopping this drug, even if told to do so by some other doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:l",
"1ff8",
"ims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691456",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heart attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop strokes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart treatment to protect the arteries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of heart attacks in patients who have unstable angina or mild heart attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clopidogrel or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703718",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stent patients: Talk with your heart doctor before stopping this drug for any reason.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stomach ulcer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bruising.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nosebleed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-o 1ff8 s drugH1Div\" id=\"F10020830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in skin color to black or purple.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul 1eef c lass=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12311 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21685=[""].join("\n");
var outline_f21_11_21685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153627\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020821\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020823\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020822\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020827\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020828\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020830\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020825\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020826\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020831\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020832\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=related_link\">",
"      Clopidogrel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/49/16152?source=related_link\">",
"      Clopidogrel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_11_21686="Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation";
var content_f21_11_21686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21686/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21686/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21686/contributors\">",
"     Ziyad M Hijazi, MD, MPH, FAAP, FACC, FSCAI, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21686/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21686/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21686/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21686/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/11/21686/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two principal goals of therapy in atrial fibrillation (AF) are to alleviate symptoms and to reduce the rate of systemic embolism (particularly stroke). Most patients with AF are treated with either a rhythm or rate control strategy to improve symptoms, and irrespective of strategy, most require chronic anticoagulation (except those deemed to be at very low risk for embolic events). Two additional limitations of antiarrhythmic drugs for rhythm control are inconsistent efficacy and frequent side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations also apply to patients with paroxysmal AF, most of whom have a risk of stroke that is similar to patients with persistent AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link\">",
"     \"Paroxysmal atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are varying degrees of risk associated with anticoagulation and not all individuals are candidates for this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal approach to reduce the risk of embolization in such patients is not clear. Nonpharmacologic strategies to prevent recurrent AF, such as radiofrequency catheter ablation, might reduce the risk of embolic stroke. However, there are only limited data confirming such a benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with nonvalvular AF, the vast majority of thrombi is located within or involves the left atrial appendage (LAA). The fibrillating LAA is a cul-de-sac that creates an appropriate milieu for blood stasis and thrombus formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H621955964#H621955964\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Mechanism of thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of the LAA in thromboembolic risk among patients with AF provides the rationale for ligation, amputation, or occlusion of the LAA in patients who are candidates for but cannot receive oral anticoagulation. Surgical and percutaneous approaches, often referred to as LAA exclusion procedures, that mechanically prevent embolization of LAA thrombi have been developed and tested. This topic will discuss these procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURGICAL LAA LIGATION OR AMPUTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical ligation or amputation of the LAA (which may be performed in patients who are undergoing cardiac surgery for other indications) is such a technique. However, there are limited data suggesting that this approach can reduce the risk of stroke. This issue was addressed in an early retrospective study of 205 patients who underwent mitral valve replacement (83 percent for rheumatic heart disease, 86 percent in AF); ligation of the LAA was performed in 58 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/2\">",
"     2",
"    </a>",
"    ]. After almost six years, the incidence of an embolic event in those with LAA ligation was significantly lower than in those without this procedure (3 versus 17 percent).",
"   </p>",
"   <p>",
"    However, one limitation to LAA ligation is that it may be incomplete, as detected by transesophageal echocardiography. The incidence of incomplete LAA ligation was 22 percent in two series with a total of 108 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Such patients continue to be at risk for LAA thrombus and thromboembolic events.",
"   </p>",
"   <p>",
"    Despite the limitations of the data supporting its use, such as small numbers of patients and potential for selection bias, ligation of the LAA at the time of mitral valve surgery has now become standard care in many centers with expertise in this technique; it is also part of the maze procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\", section on 'Maze operation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease recommended amputation of the LAA at the time of mitral valve surgery to reduce the likelihood of postoperative thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS LAA OCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occlusion of the left atrial appendage (LAA) using less invasive percutaneous, catheter-based methods has been described since 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/6\">",
"     6",
"    </a>",
"    ]. Preliminary studies of two systems specifically designed for this purpose (PLAATO and WATCHMAN systems) have been completed. Both systems deploy a device that is placed in the LAA that crosses the intraatrial septum (through a patent foramen ovale or transseptal puncture). To date, percutaneous LAA occlusion with these systems remains experimental and is not approved by the United States Food and Drug Administration for clinical use.",
"   </p>",
"   <p>",
"    In addition to these two systems, the Amplatzer cardiac plug and the LARIAT (snare device) system are also available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/62/36837?source=see_link\">",
"     \"Devices for percutaneous closure of a secundum atrial septal defect\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     PLAATO system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The percutaneous LAA transcatheter occlusion (PLAATO) system involves a device that is placed in the LAA via a transseptal catheter. The device has a self-expanding nitinol frame that is covered by a fabric that is impermeable to blood, thus sealing the LAA and preventing thrombus formation or dislodgement.",
"   </p>",
"   <p>",
"    Initial small series demonstrated successful implantation without evidence of adverse effects on the structure or function of the left atrium or left upper pulmonary vein [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A larger experience comes from the European PLAATO feasibility trial in which the device was successfully deployed in 101 of 103 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/8\">",
"     8",
"    </a>",
"    ]. Adverse outcomes at a mean of 10 months included pericardial effusion requiring therapy in eight patients, two strokes, two transient ischemic attacks, and three nonprocedural deaths.",
"   </p>",
"   <p>",
"    A combined feasibility study included 111 patients at high risk for stroke but with contraindications to chronic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    indefinitely and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for up to six weeks after device implantation. LAA occlusion was successful in 98 percent of cases. However, at nearly 10 months, there were seven major adverse events in five patients (stroke, cardiac or neurologic death, myocardial infarction, or requirement for procedure-related cardiac surgery within one month). In addition, two strokes and three transient ischemic attacks occurred at one year. The manufacturer has discontinued development of the PLAATO device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     WATCHMAN device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WATCHMAN device also involves an expandable device deployed in the LAA via a transseptal catheter (",
"    <a class=\"graphic graphic_figure graphicRef61636 \" href=\"UTD.htm?22/26/22950\">",
"     figure 1",
"    </a>",
"    ). The implanted device has a self-expanding nitinol frame to secure it in the LAA. In contrast to the PLAATO device, the fabric of the WATCHMAN device is permeable to blood. For this reason, patients require conventional thromboembolic prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    until the device is endothelialized (eg, at least 45 days post-implant), at which time transesophageal echocardiography is performed to insure endothelialization. In addition, all patients are treated with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (81 to 325 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75 mg) daily for six months.",
"   </p>",
"   <p>",
"    The WATCHMAN device was evaluated in the PROTECT AF non-inferiority trial in which over 700 patients with nonvalvular AF were randomly assigned in a 2:1 ratio to either the device (with the above antithrombotic regimen) or to long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (international normalized ratio 2.0 to 3.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/10\">",
"     10",
"    </a>",
"    ]. Inclusion criteria allowed for patients with paroxysmal, persistent, or permanent AF and all patients had a CHADS2 score &ge;1 (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). Device implantation was successful in 91 percent of all patients in whom it was attempted. The composite primary efficacy endpoint included stroke, systemic embolism, and cardiovascular death; the primary safety endpoint was a composite of major bleeding, pericardial effusion, procedure related stroke, and device embolization. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After a mean follow-up of 18 months, the primary efficacy event rate was similar in the intervention control groups (3.0 versus 4.9 events per 100 patient years respectively; rate ratio 0.62, 95% Bayesian credible interval 0.35-1.25). After a mean follow-up of 2.3 years, the primary efficacy event rates were 3.0 and 4.3 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/11\">",
"       11",
"      </a>",
"      ]. These results allowed for a finding of non-inferiority of the device with its antithrombotic protocol compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The primary safety endpoint occurred significantly more often in the device group (7.4 versus 4.4 events per 100 patient-years respectively; rate ratio 1.69, 95% Bayesian credible interval 1.01-3.19). Most of the events in the device group occurred early. Of these about 50 percent were pericardial effusions requiring drainage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two later reports from PROTECT AF increase our understanding of the potential benefits and limitations of the WATCHMAN device:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outcomes were compared between the 542 patients in the randomized study and 460 patients in the nonrandomized Continued Access Protocol (CAP) registry who underwent WATCHMAN implantation after the randomized trial was completed [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/12\">",
"       12",
"      </a>",
"      ]. There was a significant decline in the rate of procedure or device related safety events within seven days compared to those in the randomized trial (7.7 versus 3.7 percent respectively). This report raises the possibility of improved outcomes with device implantation with increased operator experience.",
"     </li>",
"     <li>",
"      In a retrospective review of 6 and 12 month follow-up echocardiograms in over 400 patients who received the WATCHMAN device, there was no significant increase in the rate of thromboembolism in the 32 percent of patients with incomplete left atrial appendage sealing (and consequent peri-device residual blood flow) compared to those without [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until the benefits and risks of the WATCHMAN device are clarified with additional data, and ultimately approved for use by regulatory agencies (it has limited approval for use in France and Germany), clinicians should consider its use only in highly selected patients in whom long-term anticoagulant therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or alternate agents is contraindicated. This device has not been approved for use in all countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354323421\">",
"    <span class=\"h2\">",
"     Other devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Amplatzer Cardiac plug is another device designed specifically for closure of the LAA and is undergoing clinical trials (",
"    <a class=\"graphic graphic_figure graphicRef82936 \" href=\"UTD.htm?17/39/18038\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/14\">",
"     14",
"    </a>",
"    ]. This device is Nitinol based and consists of a left atrial disk and a distal plug connected to the left atrial disk by a short waist. The distal plug contains six pairs of barbs designed to increase stability within the appendage. This device is shorter than the Watchman device and may be more advantageous in individuals with the variable morphology of the appendage. Animal data have been published demonstrating uncomplicated device delivery with complete occlusion of the appendage at 30-day follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LARIAT system is a non-surgical device approved by the United States (US) Food and Drug Administration (FDA) for soft tissue closure (&ldquo;approximation&rdquo;) only [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. It is has been evaluated for efficacy and safety (but not specifically approved) in the U.S. for occlusion of the LAA in patients who cannot take oral anticoagulation and are at high risk for stroke due to AF. The LARIAT system places a lasso around the LAA and then &ldquo;ties it off&rdquo; from inside the pericardial space. Patients who have had prior cardiac surgery are not candidates for this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13459530\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines for patients undergoing mitral valve surgery recommend LAA obliteration or exclusion at the time of surgical approaches for the ablation of AF (ie, the maze procedure) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 focused update of the European Society of Cardiology guidelines for the management of AF makes a weak recommendation for the use of interventional, percutaneous LAA closure in patients with a high stroke risk and contraindication for long-term anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21686/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13459485\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with atrial fibrillation (AF) are at increased risk of arterial embolization and should be risk stratified and treated to mitigate their risk irrespective of a rate or a rhythm control strategy. This recommendation applies even in those where a rhythm control strategy has proven to be successful in suppressing further episodes of atrial fibrillation. Anticoagulation is recommended for many such patients to reduce the risk, but many choose not to adhere to this recommendation. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction and rationale'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients with nonvalvular AF, the majority of thrombi are located within or involve the left atrial appendage (LAA). The importance of the LAA in thromboembolic risk among patients with AF provides the rationale for ligation, amputation, or occlusion of the LAA in patients who are candidates for but cannot receive oral anticoagulation. Surgical and percutaneous approaches (often referred to as LAA exclusion procedures) that mechanically prevent embolization of LAA thrombi have been developed and tested.",
"   </p>",
"   <p>",
"    The following summarizes important points regarding nonpharmacologic therapy to prevent embolization in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ligation of the left atrial appendage (LAA) at the time of mitral valve surgery is standard care in many centers with expertise in this technique, especially when a surgical MAZE procedure is performed concomitantly. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Surgical LAA ligation or amputation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occlusion of the LAA can be attempted using less-invasive percutaneous, catheter-based methods. The WATCHMAN device was as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      in one randomized trial, but complications of the procedure (such as pericardial effusion) occurred more frequently with the device. The WATCHMAN device is undergoing further evaluation in clinical trials and has not been approved for general use by the FDA. The role of the WATCHMAN device in clinical practice remains to be established as investigation of its risks and benefits are ongoing. There is currently no recommendation on its use at this time. A second LAA occlusion device (Amplatzer cardiac plug), developed by the same company that makes the Amplatzer ASD occlusion device, is also being evaluated in clinical trials. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Percutaneous LAA occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The LARIAT device is approved by the United States Food and Drug Administration to exclude soft tissue structures. It has been evaluated, but not approved, for use as a tool to ligate the LAA. (See",
"      <a class=\"local\" href=\"#H354323421\">",
"       'Other devices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/1\">",
"      Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012; 126:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/2\">",
"      Garc&iacute;a-Fern&aacute;ndez MA, P&eacute;rez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003; 42:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/3\">",
"      Katz ES, Tsiamtsiouris T, Applebaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol 2000; 36:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/4\">",
"      Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008; 52:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/5\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/6\">",
"      Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002; 105:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/7\">",
"      Hanna IR, Kolm P, Martin R, et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J Am Coll Cardiol 2004; 43:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/8\">",
"      Sousa JE, Costa MA, Tuzcu EM, et al. New frontiers in interventional cardiology. Circulation 2005; 111:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/9\">",
"      Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005; 46:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/10\">",
"      Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/11\">",
"      Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/12\">",
"      Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011; 123:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/13\">",
"      Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012; 59:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/14\">",
"      Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003; 60:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/15\">",
"      Bass JL. Transcatheter occlusion of the left atrial appendage--experimental testing of a new Amplatzer device. Catheter Cardiovasc Interv 2010; 76:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/16\">",
"      Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm 2011; 8:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/17\">",
"      Lee RJ, Bartus K, Yakubov SJ. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model. Circ Cardiovasc Interv 2010; 3:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/18\">",
"      Shetty R, Leitner JP, Zhang M. Percutaneous catheter-based left atrial appendage ligation and management of periprocedural left atrial appendage perforation with the LARIAT suture delivery system. J Invasive Cardiol 2012; 24:E289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/19\">",
"      Bartus K, Han FT, Bednarek J, et al. Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients With Atrial Fibrillation: Initial Clinical Experience. J Am Coll Cardiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/20\">",
"      Massumi A, Chelu MG, Nazeri A, et al. Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation. Am J Cardiol 2013; 111:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21686/abstract/21\">",
"      Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 928 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21686=[""].join("\n");
var outline_f21_11_21686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13459485\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURGICAL LAA LIGATION OR AMPUTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PERCUTANEOUS LAA OCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PLAATO system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WATCHMAN device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354323421\">",
"      Other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13459530\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13459485\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/928\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/928|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/26/22950\" title=\"figure 1\">",
"      WATCHMAN device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/39/18038\" title=\"figure 2\">",
"      Amplatzer plug",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/928|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/62/36837?source=related_link\">",
"      Devices for percutaneous closure of a secundum atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_11_21687="Lymphoscintigraphy of early breast cancer";
var content_f21_11_21687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoscintigraphy of early breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A (anterior projection) and B (lateral projection): Lymphoscintigraphy using technetium sulfur colloid demonstrates two foci of posterior and superior migration of the radiopharmaceutical into the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Pierre J Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21687=[""].join("\n");
var outline_f21_11_21687=null;
var title_f21_11_21688="Overview of follicular thyroid cancer";
var content_f21_11_21688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of follicular thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21688/contributors\">",
"     Stephanie L Lee, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21688/contributors\">",
"     Sonia Ananthakrishnan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21688/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21688/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/11/21688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular thyroid cancer, a well-differentiated tumor of thyroid epithelium, is the second most common type of thyroid cancer after papillary thyroid cancer. In iodine sufficient areas, up to 10 percent of all thyroid cancers are follicular cancers. An overview of follicular thyroid cancer will be provided here. Papillary thyroid cancer and the management of differentiated thyroid cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link\">",
"     \"Overview of papillary thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopically, the diagnosis of follicular cancer requires distinguishing adenoma from cancer, through identification of tumor extension through the tumor capsule",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular invasion. The histology ranges from normal well-differentiated epithelium with follicular development and colloid (findings associated with a good prognosis) to poorly differentiated with solid growth, absence of follicles, marked nuclear atypia, and extensive vascular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    capsular invasion (characteristics that are associated with a worse prognosis) (",
"    <a class=\"graphic graphic_picture graphicRef65775 \" href=\"UTD.htm?20/5/20560\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Typically, the microfollicular architecture is uniform with an invariant collection of cuboidal cells lining the follicles. In addition, features consistent with papillary cancer, such as psammoma bodies and nuclear changes (ground-glass appearance, longitudinal grooves, nuclear overlapping, and inclusions), should be absent.",
"   </p>",
"   <p>",
"    There are two patterns of growth that relate to capsular invasion; minimally invasive follicular cancer (MIFC) is limited to microscopic penetration of the tumor capsule without vascular invasion, while widely invasive follicular cancer (WIFC) extends beyond the tumor capsule into blood vessels and adjacent thyroid parenchyma (",
"    <a class=\"graphic graphic_picture graphicRef75526 \" href=\"UTD.htm?25/61/26577\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51148 \" href=\"UTD.htm?17/52/18242\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Newer terminology also includes angioinvasive follicular cancer, but current prognosis scoring does not yet include this type of pathology. Angioinvasive cancer may be associated with distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less common pathologic features are associated with the variants of follicular thyroid cancer. Though considered by some to be a distinct type of tumor, H&uuml;rthle cell cancer is classified by the World Health Organization as a variant of follicular thyroid cancer. It includes the presence of a cell population of \"oncocytes,\" mostly eosinophilic oxyphilic cells with abundant cytoplasm, closely packed mitochondria, and round oval nuclei with prominent nucleoli (",
"    <a class=\"graphic graphic_picture graphicRef80758 \" href=\"UTD.htm?30/47/31474\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/4\">",
"     4",
"    </a>",
"    ]. Insular thyroid cancer (ITC), another rare subtype sometimes classified under follicular thyroid cancer, shows poor differentiation, an aggressive clinical course and an unfavorable prognosis.",
"   </p>",
"   <p>",
"    Follicular variant of papillary thyroid cancer behaves like a differentiated papillary thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link\">",
"     \"Overview of papillary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most FTCs are probably of monoclonal origin. In addition, oncogene activation is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link&amp;anchor=H14#H14\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\", section on 'Follicular thyroid cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors associated with FTC include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RAS mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Point mutations of the RAS oncogene are seen in approximately 40 percent of follicular cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/5\">",
"     5",
"    </a>",
"    ]. These mutations (N-RAS, H-RAS and K-RAS, in order of decreasing frequency) occur more commonly in follicular thyroid cancers than in follicular adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. RAS mutations are not specific to follicular thyroid cancer; they also account for a small portion of papillary thyroid cancers, particularly the follicular-variant papillary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RAS mutations in follicular thyroid cancer appear to be associated with more aggressive cancers and higher mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, RAS mutations may be found in undifferentiated and anaplastic thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/8\">",
"     8",
"    </a>",
"    ]. These observations suggest that RAS mutation genotyping may assist in identifying follicular thyroid cancer patients with a poor prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     PAX8-PPAR gamma 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAX8-PPAR gamma 1 is a gene rearrangement seen in follicular adenomas and cancers. This fusion protein of a thyroid-specific transcription factor (PAX8) and a nuclear receptor, peroxisome proliferator-activated receptor gamma, is associated with approximately 10 percent of follicular adenomas and 41 percent of follicular cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/9\">",
"     9",
"    </a>",
"    ]. This fusion protein may help distinguish follicular adenoma from follicular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/10\">",
"     10",
"    </a>",
"    ]. It is thought that PAX8-PPAR gamma induces a negative effect on thiazolidinedione activation by PPAR gamma 1, leading to loss of growth inhibitory controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fact that FTC contains either RAS mutations or a PAX8-PPAR gamma 1 rearrangement, but not both, indicates that similar, yet distinct molecular events may originate with these two oncogenes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine may also play a role in the etiology of follicular thyroid cancer. In iodine-deficient regions of the world, there is a higher prevalence of follicular cancer, compared with iodine sufficient regions. With the introduction of iodine, the incidence of follicular thyroid cancer decreased, while papillary thyroid cancer increased, as seen in Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Data on the impact of iodine supplementation on mortality from follicular thyroid cancer are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors, such as p53, c-myc, c-fos and TSH receptor mutations, have also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Unlike papillary thyroid cancer, follicular thyroid cancer is rarely associated with radiation exposure, RET-PTC mutations, or BRAF mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In addition, follicular cancer is not associated with familial neoplastic syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular cancer tends to occur in an older population when compared with other differentiated thyroid cancers. Its peak incidence is between ages 40 and 60 years (",
"    <a class=\"graphic graphic_figure graphicRef81732 \" href=\"UTD.htm?42/30/43489\">",
"     figure 1",
"    </a>",
"    ), as compared with papillary thyroid cancer incidence peaking earlier, between the ages of 30 to 50 years. In addition, follicular thyroid cancer is approximately three times more common in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroid nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of follicular thyroid cancer usually occurs during the evaluation of a cold thyroid nodule. The evaluation of a thyroid nodule is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .) Features of the evaluation that pertain to follicular thyroid cancer are summarized below.",
"   </p>",
"   <p>",
"    Thyroid ultrasonography is used to answer questions about the size of the nodule and anatomy of the thyroid gland and adjacent structures in the neck. The assessment of nodule size is an important consideration for follicular thyroid cancer because increased size is associated with worse prognosis (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prognostic features'",
"    </a>",
"    below). There are certain ultrasound findings that are associated with an increased risk of follicular thyroid cancer. Nodules that are iso- to hyperechoic in texture with a thick and irregular halo, and without microcalcifications, are suspicious for follicular thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the predictive value of these characteristics varies widely, and there are no specific sonographic features of nodules that can consistently identify a malignant nodule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Criteria for identifying cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fine needle aspiration (FNA) is the diagnostic tool of choice in evaluating thyroid nodules, exceeding the utility of physical exam, laboratory evaluation, and imaging tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    .) Indications for FNA are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Fine needle aspiration biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike for papillary thyroid cancer, FNA biopsy cannot diagnose follicular thyroid cancer because it cannot distinguish between follicular adenomas and cancers. These specimens are often indeterminant lesions, categorized as follicular neoplasms or follicular lesions of undetermined significance, with epithelial cells arranged in a pattern of microfollicles, scant or absent colloid, and few macrophages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=see_link&amp;anchor=H3#H3\">",
"     \"Atlas of thyroid cytopathology\", section on 'Follicular neoplasm/microfollicular cytology'",
"    </a>",
"    .) The actual diagnosis of follicular thyroid cancer requires pathologic evaluation of the thyroid after surgery, and the identification of tumor capsule",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular invasion.",
"   </p>",
"   <p>",
"    Several approaches are under investigation to improve upon cytology alone for the assessment of follicular lesions. These include the use of PET scans, RT-PCR measurement of thyroglobulin mRNA, cellular and molecular markers. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=see_link&amp;anchor=H15#H15\">",
"     \"Thyroid biopsy\", section on 'Follicular neoplasm (microfollicular)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the identification of a follicular lesion on FNA cytology specimen, diagnostic protocols can include thyroid scan with radioactive iodine to exclude an autonomously functioning hot nodule, which would be less likely to be malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/21\">",
"     21",
"    </a>",
"    ]. Any non-autonomous nodule should be removed surgically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lymph node involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;These tumors are more typically uninodular when compared with papillary thyroid cancer. While vascular invasion is frequent with follicular cancer, spread to lymph nodes is uncommon, occurring in only 8 to 13 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, lymph node involvement is very common in papillary thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of papillary thyroid cancer\", section on 'Pathologic features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular thyroid cancer typically spreads via hematogenous dissemination. Distant metastases occur in 10 to 15 percent of patients with follicular cancer, even in those with small primary tumors, although tumors &lt;2 cm in size have not been associated with metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/23\">",
"     23",
"    </a>",
"    ]. Common sites of distant metastases are bone (with lytic lesions) and lung and, less commonly, the brain, liver, bladder and skin (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50158 \" href=\"UTD.htm?28/55/29566\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although rare, functional thyroid cancer metastases can cause symptomatic hyperthyroidism. Nearly all patients reported have had widely metastatic follicular thyroid cancer, often involving bone among other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The majority of patients with functional thyroid cancer metastases have had high serum T3 but normal T4 concentrations (T3-thyrotoxicosis). The mechanism is high activity of the type 1 and type 2 iodothyronine deiodinases in tumor tissues, ie, exogenously administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    is converted to T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/27\">",
"     27",
"    </a>",
"    ]. The functional metastases can be identified by whole body radioiodine imaging. A few of these patients have also had serum TSH-receptor stimulating antibodies, the presence of which would be expected to increase the hormonal synthetic capacity of the cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/26\">",
"     26",
"    </a>",
"    ]. The most appropriate treatment for these patients is radioactive iodine, although antithyroid drugs can also be used to ameliorate the hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for differentiated thyroid cancers is best for young patients who have minimal capsular and vascular invasion. Given that follicular cancer typically occurs in older patients, it is more commonly associated with an aggressive clinical course, distant metastases, and higher mortality than papillary thyroid cancer. Women may have a better prognosis than men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;To assist in staging differentiated thyroid cancers, the American Joint Committee on Cancer and the International Union Against Cancer",
"    <span class=\"nowrap\">",
"     (AJCC/UICC)",
"    </span>",
"    staging schema (based on pTNM parameters) is recommended for all patients because of its utility in predicting disease mortality, and its requirement for cancer registries (although it may misclassify some younger patients with advanced disease). The use of other postoperative clinico-pathologic staging systems, including CAEORTC, AGES, AMES, U of C, MACIS, OSU, MSKCC, and NTCTCS systems, allows accurate identification of the majority of patients (70 to 85 percent) who have a low mortality risk and for planning follow-up evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14599?source=see_link\">",
"     \"Clinicopathologic staging of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age is a significant prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. The 10-year survival rate for patients with differentiated thyroid cancer is over 95 percent if the patient is less than 40 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients in whom the diagnosis occurs between ages 40 to 59 years have an 80 percent 10-year survival rate. Typically, patients over the age of 40 will have a more aggressive tumor, and are less likely to respond to radioiodine therapy. It is also likely that younger patients have cancers that are more responsive to therapy with surgery and RAI than are older adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tumor characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other prognostic factors associated with higher mortality include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distant metastasis &mdash; Up to 25 percent of cases of follicular thyroid cancer may include distant metastasis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vascular invasion.",
"     </li>",
"     <li>",
"      Capsular extension &mdash; Minimally invasive follicular cancer has been associated with good survival and is considered low-risk when compared with widely invasive follicular cancer (WIFC). WIFC typically occurs in an older population, with larger tumor size, invasion into the thyroid, and distant metastases. When both extensive capsule and vascular invasion are present, distant metastases are present in more than 50 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tumor size &mdash; Unlike papillary thyroid cancer, no \"occult\" follicular thyroid cancer or microcarcinoma with minimal mortality risk exists. Smaller tumors should be examined using the same risk categories as used with larger tumors. There is a linear relationship when comparing the size of the tumor to cancer mortality and recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early recurrence, which more commonly occurs in older male patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      H&uuml;rthle cell carcinoma, a variant of follicular thyroid cancer, may be associated with poorer prognosis than follicular cancer, perhaps related to the tumor's poor affinity for taking up radioactive iodine. In one study, the 10-year disease free interval was 75 percent for follicular cancer and 41 percent for H&uuml;rthle cell cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/31\">",
"       31",
"      </a>",
"      ]. H&uuml;rthle cell has been shown to have an increased recurrence rate in local lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insular cancer, a poorly differentiated follicular thyroid cancer variant, also carries a poor prognosis as it is commonly found to be an invasive tumor with extensive regional and distant metastasis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment options available for follicular thyroid cancer are the same as for all differentiated thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimum treatment, however, remains controversial, as there is a lack of randomized control trials comparing various modalities, due to the difficulty in following a slow-growing disease. The treatment modalities address treatment of the primary lesion, adjuvant therapy, and identification and treatment of recurrence. An important part of treatment is continued reassessment of the risks of recurrence and mortality as new information is gathered during follow-up evaluations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of surgery is to remove any cancer in the neck, including thyroid tissue and metastatic cervical lymph nodes. Total or near-total thyroidectomy is indicated in all patients with follicular cancer who are &ge;45 years and also in those under 45 years who have tumor greater than 4 cm, the presence of macroscopic multifocality, macroscopic invasion of either the tumor capsule or extrathyroidal tissues, poor differentiation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extracervical metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Total thyroidectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a thyroid lobectomy is performed and the post-operative review of the surgical section reveals an unexpected follicular cancer, completion thyroidectomy should be scheduled within days to weeks before significant scarring develops [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/34\">",
"     34",
"    </a>",
"    ]. Alternatively, radioactive iodine can be used at lower doses to ablate the remaining thyroid tissue, especially if the patient is a poor surgical candidate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/35\">",
"     35",
"    </a>",
"    ]. Higher doses of radioactive iodine are not recommended initially due to the associated morbidities of I-131 doses in thyroid cancer patients, including pain, swelling, and risk of whole body radiation, given the increased uptake by larger amounts of remaining thyroid tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because lymph node metastasis are less common in follicular than in papillary thyroid cancer, near-total or total thyroidectomy without lymph node dissection, followed by radioactive iodine therapy, may be appropriate for patients with follicular thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, preoperative assessment for cervical lymph nodes using ultrasound should be performed. Preoperative ultrasound can assist in identifying suspicious cervical adenopathy in 20 to 31 percent of cases and may alter the surgical approach, although up to half of nodes may be missed due to the overlying thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. If suspicious nodes are found, FNA should be performed to confirm malignancy. Compartment resection of bilateral central (level VI) lymph nodes should be performed with additional levels to be resected if clinically evident adenopathy is found on pre-operative ultrasound or other imaging modalities or on intraoperative exploration. These lymph nodes should be removed by total compartment resection, because RAI therapy may not completely ablate the macroscopic metastases in the nodes. Radical neck dissections are typically not necessary for well-differentiated follicular cancer, and have not been shown to reduce recurrence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications arising from thyroidectomy performed by an experienced surgeon are uncommon. Possible risks include recurrent laryngeal nerve damage, transient or permanent hypoparathyroidism, and postoperative hematoma. These complications are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H15#H15\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Radioactive iodine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioactive iodine (RAI) is typically used as treatment for differentiated thyroid cancers. Treatment of follicular thyroid cancer is identical to the treatment of papillary thyroid cancer. Given that follicular thyroid cancer commonly presents with more advanced disease, RAI is typically administered following thyroid surgery for remnant ablation and adjuvant cancer therapy. The purpose is to destroy the remaining functioning tissue in the thyroid bed, whether it be malignant or not, as well as any microscopic metastatic disease. RAI is less effective for local or distant macroscopic metastases, particularly those that are &gt;1 cm in size, especially in bone. In these cases, surgical resection or radiation therapy should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goals of RAI ablation include a reduction in the recurrence rate, improvement in survival, destruction of the thyroid remnant to provide better identification of metastases or recurrence on whole body scans, and utilization of thyroglobulin as a marker of tumor persistence or recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/39\">",
"     39",
"    </a>",
"    ]. Further details of treatment using RAI, including preparation of patients for RAI, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thyroid hormone replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following RAI therapy, thyroid hormone replacement is reinstated with a goal of keeping the TSH subnormal or suppressed. Although there are no available clinical trial data, observational data suggest that thyroid hormone suppression improves outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The degree of TSH suppression is controversial due to risks of accelerated bone loss in postmenopausal women and atrial fibrillation.",
"   </p>",
"   <p>",
"    We agree with the American Thyroid Association, which suggests that high-risk patients should have TSH suppression to below 0.1",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    while low-risk patients should be suppressed to slightly below the lower limit of normal (0.1 to 0.5",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/33\">",
"     33",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other less common treatment modalities for follicular thyroid cancer include external beam radiotherapy (EBRT) and chemotherapy. EBRT is typically reserved for older patients with non-resectable metastatic disease that does not take up iodine or has been resistant to therapy with RAI. Pain relief for bony lesions and spinal cord compression may also indicate a need for EBRT. EBRT may be more effective when given with chemotherapy including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy regimens (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) may also be indicated for disease that has been refractory to RAI and EBRT and is found to be unresectable [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/43\">",
"     43",
"    </a>",
"    ]. There are several ongoing clinical trials using agents that target vascular invasion and unique cellular activities, but no results have been documented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28345?source=see_link\">",
"     \"Chemotherapy for differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring patients thought to be disease free for recurrence is an important goal for long-term therapy. Methods of evaluation for recurrence depend upon initial therapy and risk of recurrence, and should be individualized for each patient. Testing includes monitoring basal and TSH stimulated thyroglobulin concentrations, serial neck ultrasounds, whole body RAI scanning, and 18FDG-PET scanning in RAI non-avid disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Long-term follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/10/36002?source=see_link\">",
"       \"Patient information: Thyroid cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follicular thyroid cancer, a well-differentiated tumor of thyroid epithelium, is the second most common type of thyroid cancer after papillary thyroid cancer. It is more common in iodine deficient areas, and tends to occur in an older population when compared with papillary thyroid cancer. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of follicular thyroid cancer usually occurs during the evaluation of a cold thyroid nodule. FNA biopsy alone cannot distinguish between follicular adenomas and cancers. Microscopically, the diagnosis of follicular cancer requires identification of tumor extension through the tumor capsule",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular invasion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most FTCs contain either RAS mutations or a PAX8-PPAR gamma 1 rearrangement but not both, indicating that similar yet distinct molecular events may originate with these two oncogenes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Molecular pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important prognostic features include stage, age, and tumor characteristics (tumor size, vascular invasion, capsular extension, histologic grade, and distant metastases). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognostic features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment options available for follicular thyroid cancer are the same as for all differentiated thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21688/abstract/33\">",
"     33",
"    </a>",
"    ]. The optimum treatment however, remains controversial, as there is a lack of randomized control trials comparing various modalities in follicular thyroid cancer. Therefore, treatment strategies for follicular thyroid cancer are based primarily upon indirect evidence from papillary thyroid cancer data. Treatment should be based upon risk assessment of each individual patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with possible follicular thyroid cancer, we recommend a total or near-total thyroidectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Surgical management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link\">",
"       \"Surgical treatment of differentiated thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the diagnosis of follicular thyroid cancer is confirmed surgically, we recommend treatment with I-131 for ablation of any remaining functioning tissue in the thyroid bed, whether it be malignant or not, as well as any microscopic metastatic disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We ablate the majority of our patients to allow accurate staging using a post-therapy scan, and for long-term assessment of recurrence using serum thyroglobulin. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Radioactive iodine therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link\">",
"       \"Radioiodine treatment of differentiated thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After surgery and radioiodine ablation, we recommend thyroid hormone replacement to suppress serum TSH concentrations (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The degree of suppression should be based upon the patient's prognosis, and the presence of any underlying heart disease. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Thyroid hormone replacement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone suppression'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other aspects of treatment and monitoring differentiated thyroid cancer are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/1\">",
"      Collini P, Sampietro G, Rosai J, Pilotti S. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch 2003; 442:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/2\">",
"      D'Avanzo A, Treseler P, Ituarte PH, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer 2004; 100:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/3\">",
"      Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 2001; 11:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/4\">",
"      Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009; 19:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/5\">",
"      Medema RH, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog 1993; 4:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/6\">",
"      Lemoine NR, Mayall ES, Wyllie FS, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988; 48:4459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/7\">",
"      Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003; 120:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/8\">",
"      Garcia-Rostan G, Zhao H, Camp RL, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21:3226.",
"     </a>",
"    </li>",
"    <li>",
"     Fagin JA. Molecular genetics of tumors of thyroid follicular cells. In: Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2005. p.909.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/10\">",
"      Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002; 87:3947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/11\">",
"      Martelli ML, Iuliano R, Le Pera I, et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002; 87:4728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/12\">",
"      Pettersson B, Adami HO, Wilander E, Coleman MP. Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type. Int J Cancer 1991; 48:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/13\">",
"      Harach HR, Escalante DA, Onativia A, et al. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol (Copenh) 1985; 108:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/14\">",
"      PENDERGRAST WJ, MILMORE BK, MARCUS SC. Thyroid cancer and thyrotoxicosis in the United States: their relation to endemic goiter. J Chronic Dis 1961; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/15\">",
"      Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004; 15:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/16\">",
"      F&uuml;hrer D, Tannapfel A, Sabri O, et al. Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. Endocr Relat Cancer 2003; 10:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/17\">",
"      Cerilli LA, Mills SE, Rumpel CA, et al. Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol 2002; 118:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/18\">",
"      Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LAG, Eisner MP, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute. Bethesda, MD, 2004. file://seer.cancer.gov/csr/1975_2001/ (Accessed on October 22, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/20\">",
"      Jeh SK, Jung SL, Kim BS, Lee YS. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. Korean J Radiol 2007; 8:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/21\">",
"      Heged&uuml;s L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351:1764.",
"     </a>",
"    </li>",
"    <li>",
"     Rosai, J, Carcangiu, ML, De Lellis, RA. Tumors of the thyroid gland. In: Atlas of tumor pathology, 3rd series, fas 5. AFIP, Washington.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/23\">",
"      Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/24\">",
"      Grebe SK, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am 1995; 24:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/25\">",
"      Bowden WD, Jones RE. Thyrotoxicosis associated with distant metastatic follicular carcinoma of the thyroid. South Med J 1986; 79:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/26\">",
"      Kasagi K, Takeuchi R, Miyamoto S, et al. Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol (Oxf) 1994; 40:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/27\">",
"      Miyauchi A, Takamura Y, Ito Y, et al. 3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. J Clin Endocrinol Metab 2008; 93:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/28\">",
"      Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418.",
"     </a>",
"    </li>",
"    <li>",
"     Mazzaferri EL. Thyroid carcinoma: Papillary and follicular. In: Endocrine Tumors, Mazzaferri EL, Samaan NA (Eds), Blackwell Scientific, Cambridge, MA 1993. p.278.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/30\">",
"      Lin JD, Hsueh C, Chao TC. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 2009; 19:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/31\">",
"      Kushchayeva Y, Duh QY, Kebebew E, et al. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 2008; 195:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/32\">",
"      Lai HW, Lee CH, Chen JY, et al. Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy. J Am Coll Surg 2006; 203:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/33\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/34\">",
"      Demeure MJ, Clark OH. Surgery in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/35\">",
"      Randolph GW, Daniels GH. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. Thyroid 2002; 12:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/36\">",
"      Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003; 134:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/37\">",
"      Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/38\">",
"      Soh EY, Clark OH. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am 1996; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/39\">",
"      Ross DS. Long-term management of differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/40\">",
"      McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002; 34:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/41\">",
"      Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81:4318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/42\">",
"      Ford D, Giridharan S, McConkey C, et al. External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2003; 15:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21688/abstract/43\">",
"      Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocr Rev 1994; 15:500.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7867 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-59ED1F9292-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21688=[""].join("\n");
var outline_f21_11_21688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RAS mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PAX8-PPAR gamma 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iodine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroid nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lymph node involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSTIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tumor characteristics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surgical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Radioactive iodine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thyroid hormone replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7867\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7867|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/55/29566\" title=\"diagnostic image 1\">",
"      PET fluorodeoxyglucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7867|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/30/43489\" title=\"figure 1\">",
"      Age specific rates all thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7867|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/5/20560\" title=\"picture 1\">",
"      Follicular lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/61/26577\" title=\"picture 2\">",
"      Follicular thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/52/18242\" title=\"picture 3\">",
"      Follicular thyroid cancer magnification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/47/31474\" title=\"picture 4\">",
"      Hurthle cell lesion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=related_link\">",
"      Atlas of thyroid cytopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28345?source=related_link\">",
"      Chemotherapy for differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14599?source=related_link\">",
"      Clinicopathologic staging of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=related_link\">",
"      Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=related_link\">",
"      Overview of papillary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/10/36002?source=related_link\">",
"      Patient information: Thyroid cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28056?source=related_link\">",
"      Thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_11_21689="First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer";
var content_f21_11_21689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21689/contributors\">",
"     Thomas J Herzog, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21689/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21689/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/11/21689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics and behavior. As such, these are often combined together and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice. This topic will consider all three histologies under the heading EOC. EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women in the United States. Approximately 75 percent of women have stage III (disease that has spread throughout the peritoneal cavity or that involves lymph nodes) or stage IV (disease spread to more distant sites) disease at diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A standard approach for these patients is maximal surgical cytoreduction followed by platinum and taxane-based chemotherapy. First-line systemic chemotherapy for women with advanced EOC involving the abdomen (stage III) or extra-abdominal sites (eg, parenchymal liver or lung, stage IV) and posttreatment surveillance of EOC will be reviewed here. Initial surgical management, adjuvant therapy for women with early stage (stage I or II) disease, and the treatment of patients with relapsed or refractory EOC are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link\">",
"       Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"      </a>",
"      <br/>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       Epithelial ovarian cancer: Initial surgical management",
"      </a>",
"      <br/>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link\">",
"       Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"      </a>",
"      <br/>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"      </a>",
"      <br/>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20367464\">",
"    <span class=\"h1\">",
"     INITIAL CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary surgical cytoreduction followed by systemic chemotherapy is the preferred initial management for women with stage III or IV EOC. Patients who are not good candidates for surgery due to the location and volume of disease involvement or medical comorbidities at the time of diagnosis may be considered for neoadjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H250841373\">",
"     'Neoadjuvant chemotherapy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The two modalities used in the postoperative treatment of newly diagnosed advanced stage EOC are intravenous (IV) chemotherapy alone or a combination of IV and intraperitoneal",
"    <span class=\"nowrap\">",
"     (IV/IP)",
"    </span>",
"    chemotherapy. A choice between these options is dependent on the amount of disease remaining after surgery. Combination",
"    <span class=\"nowrap\">",
"     IV/IP",
"    </span>",
"    treatment classically is reserved for women with optimally cytoreduced EOC as defined by a postoperative residual disease no greater than one centimeter at any single site after cytoreductive surgery. Conversely, patients with greater than one centimeter of residual disease following surgery are treated with IV chemotherapy instead of IP, since IP has limited penetration into larger tumors. These two treatment options are discussed in more detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250842527\">",
"    <span class=\"h2\">",
"     Intravenous chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1980s, the standard of care for advanced EOC was the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , the efficacy of which was established by studies conducted by the Gynecologic Oncology Group (GOG) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/1\">",
"     1",
"    </a>",
"    ]. Chemotherapy for EOC has evolved remarkably since that time, with the most important contributions being the utilization of platinums and taxanes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Subsequent studies have evaluated the addition of biologics, such as the angiogenesis inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , to platinum and taxane-based treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250842535\">",
"    <span class=\"h3\">",
"     Platinum and taxane combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with advanced EOC, we and others recommend intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (typically dosed by the area under the curve [AUC] 6 [range 5-7.5]) administered with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over three hours) repeated every three weeks for six cycles (",
"    <a class=\"graphic graphic_table graphicRef65626 \" href=\"UTD.htm?6/57/7070\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Phase III studies have demonstrated that carboplatin produces equivalent response rates and survival outcomes to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , but is associated with less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. In addition, the SCOTROC study demonstrated that carboplatin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    is equivalent to carboplatin with paclitaxel, but docetaxel causes a lower incidence of neuropathy, myalgias, and weakness, though increases the risk of neutropenia, hypersensitivity reactions, and severe nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/12\">",
"     12",
"    </a>",
"    ]. Finally, the administration of treatment beyond six cycles is not associated with improved outcomes to justify the increased risk of cumulative toxicities and generally is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of both platinum salts and taxanes is highlighted in a 2006 multiple-treatment meta-analysis that included 60 trials in women (n=15,609) with EOC which showed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A platinum-based combination was better than platinum monotherapy (hazard ratio [HR] favoring the combination 1.16, 95% CI 0.86-1.58).",
"     </li>",
"     <li>",
"      A platinum-taxane combination was better than a platinum plus non-taxane combination (HR favoring platinum plus taxane 1.28, 95% CI 1.07-1.53).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is currently no role for the addition of a third chemotherapeutic agent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    as the first-line treatment of EOC. Phase III trials have failed to demonstrate a survival benefit from the addition of a third agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    , interferon gamma) to the",
"    <span class=\"nowrap\">",
"     paclitaxel/carboplatin",
"    </span>",
"    backbone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/17-23\">",
"     17-23",
"    </a>",
"    ]. Trials evaluating more intensive regimens, including high dose chemotherapy and hematopoietic cell transplantation, have not shown a survival advantage in clinical trials. As an example, a phase III trial of 149 patients with untreated EOC randomly assigned treatment following surgery to standard combination therapy or high-dose treatment with two cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and paclitaxel followed by three cycles of high-dose carboplatin and paclitaxel with autologous hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/24\">",
"     24",
"    </a>",
"    ]. Although median progression-free survival was prolonged with high-dose chemotherapy (30 versus 21 months), this did not translate in to a survival advantage; the median overall survival was 54 months in women treated with HCT and 63 months in those treated with standard chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H760222525\">",
"    <span class=\"h4\">",
"     Alternative doses and schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with advanced EOC, we recommend IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (typically dosed by the area under the curve [AUC] 6) administered with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over three hours) repeated every three weeks for six cycles (",
"    <a class=\"graphic graphic_table graphicRef65626 \" href=\"UTD.htm?6/57/7070\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Alternative regimens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"       <sup>",
"       </sup>",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (AUC=5) IV every three weeks for six cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/12\">",
"       12",
"      </a>",
"      ]. Given the risk of neutropenia, we recommend use of prophylactic growth factors during therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (135",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours) every three weeks for six cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dose-dense treatment:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      (AUC 6 on day 1) and weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, and 15) every three weeks for six cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a Japanese Gynecologic Oncology Group phase III trial involving 631 women, this dose-dense regimen was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (AUC 6 on day 1) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (180",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) with both regimens repeated every three weeks for up to nine cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/26\">",
"     26",
"    </a>",
"    ]. At a median follow-up of 29 months, dose-dense treatment showed the following results compared to every three week treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant improvement in median progression free survival (28 versus 17 months; hazard ratio for recurrence [HR] 0.71, 95% CI 0.58-0.88).",
"     </li>",
"     <li>",
"      Significant improvement in overall survival at three years (HR for mortality 0.75, 95% CI 0.57-0.98). &nbsp;",
"     </li>",
"     <li>",
"      A higher rate of treatment discontinuation for toxicity (52 versus 37 percent) and higher proportion of patients who had at least one treatment cycle delayed because of toxicity (76 versus 67 percent).",
"     </li>",
"     <li>",
"      Similar frequency of severe (grade 3 or 4) nonhematologic toxicity (including neurotoxicity).",
"     </li>",
"     <li>",
"      No difference in rate of febrile neutropenia between groups (9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dose-dense therapy treatment is delivered weekly without a week off. This lack of a treatment break and the high rates of discontinuation have limited its replacement as the standard of care in advanced EOC. We await the results of further prospective phase III trials in order to confirm the efficacy and clarify the toxicity of dose-dense treatment in non-Japanese patients before incorporating it into our standard practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284998595\">",
"    <span class=\"h4\">",
"     Incorporation of angiogenesis inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been increasing interest in the incorporation of angiogenesis inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , into the treatment for patients with EOC. Studies investigating this approach suggest that bevacizumab prolongs progression free survival (PFS) but not overall survival (OS) in this patient population. We agree with the National Comprehensive Cancer Network (NCCN) and do not administer bevacizumab routinely as part of the initial adjuvant therapy or as maintenance therapy following adjuvant therapy of advanced stage EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence on the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    as part of an initial adjuvant treatment program in women with newly diagnosed EOC comes from two trials conducted by the Gynecologic Oncology Group (GOG 218) and the International Collaborative on Ovarian Neoplasms (ICON 7). These studies are detailed here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       GOG 218",
"      </strong>",
"      &mdash; GOG 218 was a randomized placebo controlled study involving 1873 women with stage III or IV EOC who had undergone surgical cytoreduction [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/27\">",
"       27",
"      </a>",
"      ]. Women were randomly assigned to one of the following three groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Group I: Standard chemotherapy &mdash; Six cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (dosed at area under the curve [AUC] 6 on day 1) administered every 21 days. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) was allowed if patients experienced a paclitaxel-induced hypersensitivity reaction or peripheral neuropathy occurred. Patients received placebo during cycles 2 to 6 followed by placebo until month 15.",
"     </li>",
"     <li>",
"      Group II:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day 1, cycles 2 to 6) plus standard chemotherapy for six cycles followed by placebo until month 15.",
"     </li>",
"     <li>",
"      Group III:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      plus standard chemotherapy as in group II followed by bevacizumab (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day 1, every 21 days) until month 15.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the administration of standard chemotherapy, disease progression (PD) was determined by clinical exam or computed tomography of the abdomen and pelvis. However, for women who completed all six cycles of chemotherapy, PD was determined based upon these same criteria or a rising CA-125. In addition, all patients were unblinded at PD. The main study results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only 19 percent of patients completed all planned treatment (16 percent in group I, 17 percent in group II, and 24 percent in group III). The major reason for early discontinuation was PD, which occurred in 48, 42, and 26 percent, respectively.",
"     </li>",
"     <li>",
"      At a median followup of 17 months, there was no difference in PFS between group II and group I (median PFS, 10 and 11 months, respectively).",
"     </li>",
"     <li>",
"      Compared to group I, there was a significant increase in the median PFS in group III (14 months). This translated into a significant reduction in the risk of disease progression or death (hazard ratio [HR] 0.72, 95% CI 0.63-0.82).",
"     </li>",
"     <li>",
"      There was no improvement in OS; median OS across all arms was approximately 39 months.",
"     </li>",
"     <li>",
"      Compared to standard chemotherapy, women who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      plus chemotherapy experienced a slightly lower quality of life during the chemotherapy phase. Following completion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , there was no significant difference in quality of life observed. &nbsp;",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      was associated with a higher incidence of mild to serious (grade 2 or higher) hypertension (17 and 23 versus 7 percent in groups II, III and I, respectively).",
"     </li>",
"     <li>",
"      The incidence of GI perforation or fistula formation was 3 percent in both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      containing arms versus 1 percent in the chemotherapy alone arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although actual cost data were not collected in GOG-218, a subsequent modeled cost-effectiveness analysis using the available data on PFS and OS concluded that the cost-effectiveness ratio for the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to standard chemotherapy was unfavorable [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       ICON7",
"      </strong>",
"      &mdash; The Gynecologic Intergroup Trial (ICON7) randomly assigned 1528 previously untreated women with high-risk early stage (I or IIA clear cell or grade 3) or advanced EOC to standard chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      AUC 5 or 6 and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for six cycles with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      during chemotherapy and then as maintenance treatment for 12 additional cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike GOG 218, over 90 percent of patients completed assigned treatment. Of those assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , 62 percent completed the maintenance phase. Compared to standard chemotherapy, the incorporation of bevacizumab resulted in [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant increase in the overall response rate (67 versus 48 percent).",
"     </li>",
"     <li>",
"      Significant improvement in the median PFS at 42 months follow-up (24 versus 22 months).",
"     </li>",
"     <li>",
"      No significant difference in overall survival.",
"     </li>",
"     <li>",
"      More serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse events (66 versus 56 percent) including a higher rate of mild to serious (grade 2 or higher) hypertension (18 versus 2 percent).",
"     </li>",
"     <li>",
"      No difference in global quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women at high-risk for progression (stage III with &gt; 1.0 cm residual disease at the end of surgery or stage IV),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was associated with significant improvement in PFS (18 versus 14 months, respectively) and OS (37 versus 29 months). However, this analysis was a posthoc subgroup analysis and requires prospective validation before being accepted as a definitive result.",
"   </p>",
"   <p>",
"    While both studies show a benefit in PFS with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , it has been shown only when bevacizumab is administered along with chemotherapy and then as a maintenance treatment. Given that concurrent bevacizumab and chemotherapy (without maintenance bevacizumab) did not improve PFS compared to chemotherapy alone, the role of bevacizumab with chemotherapy is unresolved. Until long-term quality of life and survival outcomes are reported, we suggest not adding bevacizumab routinely to upfront chemotherapy or as a maintenance treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250842013\">",
"    <span class=\"h2\">",
"     Intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have had a complete cytoreduction or those optimally cytoreduced (ie, to less than one centimeter postoperative residual disease at any one site) we recommend a combined regimen with a component of intravenous delivered chemotherapy",
"    <span class=\"nowrap\">",
"     (IV/IP).",
"    </span>",
"    The rationale and management of IP chemotherapy for ovarian cancer is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/537?source=see_link\">",
"     \"Intraperitoneal chemotherapy for treatment of ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the unique pattern of spread of EOC, the bulk of disease is found within the peritoneal cavity. Intraperitoneal (IP) therapy can permit more than a several-fold increase in drug concentration in the abdominal cavity compared to systemic administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Despite this regional advantage, penetration into tumor tissue may be limited, thus limiting its use in women who have been suboptimally cytoreduced (ie, more than one centimeter of residual disease left behind following initial surgery).",
"   </p>",
"   <p>",
"    For women with optimally cytoreduced stage III EOC who are not candidates for IP therapy due to medical comorbidities, borderline performance status, or other clinical reasons, we prefer to administer IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H250842535\">",
"     'Platinum and taxane combination therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Support for",
"    <span class=\"nowrap\">",
"     IV/IP",
"    </span>",
"    chemotherapy comes from two meta-analyses and eight randomized trials that compared standard intravenous therapy with",
"    <span class=\"nowrap\">",
"     IV/IP",
"    </span>",
"    treatment following primary cytoreductive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first analysis consisted of eight randomized trials and included over 1800 women receiving primary therapy for advanced EOC [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/32\">",
"       32",
"      </a>",
"      ]. This demonstrated that",
"      <span class=\"nowrap\">",
"       IV/IP",
"      </span>",
"      treatment was associated with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reduction in the risk of dying compared to IV treatment (HR 0.79, 95% CI 0.70-0.90)",
"     </li>",
"     <li>",
"      Improvement in disease free survival (HR for recurrence 0.79, 95% CI 0.69-0.90)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The second meta-analysis included studies conducted between January 1990 and January 2006 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/33\">",
"       33",
"      </a>",
"      ]. Encompassing six randomized trials of 1716 women, it confirmed the prior study&rsquo;s findings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       IV/IP",
"      </span>",
"      treatment was associated with an improvement in PFS compared to IV treatment (HR for recurrence 0.79, 95% CI 0.69-0.91).",
"     </li>",
"     <li>",
"      It was also associated with an improvement in OS (HR for mortality 0.80, 95% CI 0.702-0.910).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most commonly used",
"    <span class=\"nowrap\">",
"     IV/IP",
"    </span>",
"    regimen comes from the Gynecologic Oncology Group (GOG) 172 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/34\">",
"     34",
"    </a>",
"    ]. In this study 429 women with optimally cytoreduced stage III EOC were randomized to either IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (135",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 24 hours on day 1) followed by IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 2) every 21 days for six cycle (standard therapy) or an",
"    <span class=\"nowrap\">",
"     IV/IP",
"    </span>",
"    regimen consisting of paclitaxel (135",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 24 hours on day 1), IP cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in a liter of warmed normal saline on day 2) and IP paclitaxel (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 8). However, the toxicity of this regimen and multi-day schedule utilized has limited its widespread use in optimally cytoreduced EOC.",
"   </p>",
"   <p>",
"    The GOG explored a modification to this schedule in a phase I feasibility (GOG 9921) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/35\">",
"     35",
"    </a>",
"    ]. Twenty women with newly diagnosed EOC were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (135",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    over three hours on day 1) immediately followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IP on day 1) and paclitaxel (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IP on day 8) As reported, 19 patients (95 percent) completed all six planned cycles. The dose-limiting toxicities consisted of a urinary tract infection with normal neutrophil count, grade 4 abdominal pain, and grade 3 hyperglycemia. The authors concluded that this modification represented a feasible alternative to GOG 172. As with other phase 1 trials, efficacy cannot be directly compared to other regimens, including GOG 172. Technical aspects in the placement of an IP port are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/537?source=see_link\">",
"     \"Intraperitoneal chemotherapy for treatment of ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284999123\">",
"    <span class=\"h3\">",
"     Hyperthermic intraoperative IP chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outside of a clinical trial, we suggest not using hyperthermic intraoperative IP chemotherapy (HIPEC) as first-line treatment. HIPEC refers to the instillation of heated chemotherapy at the time of surgery. There is growing interest in the use of HIPEC for EOC, and early data on HIPEC as a component of front line therapy of advanced EOC are encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, major concerns about this approach include its inherent potential morbidity, the lack of randomized trials confirming the theoretical advantage of hyperthermia, and that longer postoperative recovery time may result in delay, decreased dose intensity, or even withdrawal from subsequent systemic chemotherapy, thereby worsening prognosis. Further discussion of HIPEC as a potential treatment of EOC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link&amp;anchor=H16216188#H16216188\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\", section on 'Heated intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250841366\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250841373\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with advanced EOC who are poor candidates to withstand an aggressive initial surgical cytoreduction or for those with extensive disease that will preclude up front optimal cytoreduction (liver or pulmonary metastases, disease in the porta hepatis, massive ascites), we suggest neoadjuvant chemotherapy. The role of neoadjuvant chemotherapy for EOC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24472?source=see_link\">",
"     \"Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250841395\">",
"    <span class=\"h2\">",
"     In vitro chemosensitivity and resistance assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro assays of chemosensitivity or resistance, such as the Chemo-FX assay or the Extreme Drug Resistance (EDR) assay [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], are laboratory tests that have been developed as a method to select the optimal chemotherapy regimen (sensitivity assays) or identify those agents least likely to be effective (resistance assays). However, the utility of these assays have not been prospectively validated, and cost benefits have not been clearly demonstrated. We agree with the American Society of Clinical Oncology that concluded that the evidence is insufficient to justify the routine use of any of these assays outside of the clinical trial setting and that oncologists should make chemotherapy treatment recommendations on the basis of published clinical trial reports while taking into account an individual patient&rsquo;s treatment preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250841768\">",
"    <span class=\"h1\">",
"     EVALUATION AFTER CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of women after chemotherapy varies depending upon physician preference. At the completion of treatment, we perform a history and physical (including pelvic) examination and CA-125. Imaging such as computed tomography (CT) of the chest, abdomen, and pelvis may be utilized as well. Although second-look laparotomy has been used in the past to define pathologic response, results of second look laparotomy are not associated with prognosis. We recommend against a second-look operation at the end of first-line chemotherapy. The rationale and indications for second look laparotomy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25847?source=see_link\">",
"     \"Epithelial ovarian cancer: Second look surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the results of the posttreatment evaluation are normal, then a patient is considered to have a clinical complete response. However, if there is evidence of residual cancer by exam or CT, or if the CA-125 does not return to normal levels, women are considered to have platinum-resistant disease (sometimes referred to as primary refractory EOC) and should be considered for further treatment. (See",
"    <a class=\"local\" href=\"#H760206841\">",
"     'Treatment of recurrent disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1171802\">",
"    <span class=\"h1\">",
"     MAINTENANCE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with EOC achieve a complete clinical remission with first-line chemotherapy, but the majority will recur. This has led to trials of maintenance or consolidation therapy to improve the percentage of women who remain relapse-free. These efforts have focused on continuation of chemotherapy beyond the standard six cycles (maintenance chemotherapy) and short-term high dose strategies (ie, intraperitoneal [IP]) therapy, both alone and in combination with IV therapy.",
"   </p>",
"   <p>",
"    However, a meta-analysis of six randomized trials (n=902) reviewed the impact of maintenance chemotherapy for EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/42\">",
"     42",
"    </a>",
"    ]. It concluded there was no significant improvement in five-year overall survival to justify the administration of maintenance chemotherapy (relative risk 1.07, 95% CI 0.91-1.27).",
"   </p>",
"   <p>",
"    An ongoing study, GOG 212, is further investigating the role of maintenance taxanes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance, including the role of CA-125 measurements, for women who have completed treatment for ovarian cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H6099443#H6099443\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H760206841\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall likelihood of relapse after initial therapy for all stages of disease for women with EOC is 62 percent; it is 80 to 85 percent for women who present with stage III or IV disease. &nbsp;",
"   </p>",
"   <p>",
"    Recurrence can be detected either serologically using tumor markers (eg, CA-125)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by the development of clinical or radiologic signs of progression. Based on the results of the MRC05 study described above, we recommend retreatment based on signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of relapsed EOC and not treating a rising CA-125 alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H1105882#H1105882\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Role of CA-125 surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of relapsed disease is stratified based upon the amount of time that has elapsed between the completion of platinum-based treatment and the detection of relapse, known as the platinum-free interval (PFI):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a PFI of six months or longer are considered to have &ldquo;platinum sensitive&rdquo; disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a PFI of less than six months are considered to have &ldquo;platinum-resistant&rdquo; disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The PFI as a predictor of outcome was illustrated in a report on 72 patients with measurable disease recurrence who had received at least two",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -based regimens and who had a PFI of at least four months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21689/abstract/43\">",
"     43",
"    </a>",
"    ]. For those with a PFI between 5 and 12 months, the overall response rate (ORR) and complete response (CR) rate was 27 and 5 percent, respectively; for women with a PFI 13 to 24 months, it was 33 and 11 percent, respectively; and for those with a PFI &gt; 24 months, it was 59 and 22 percent, respectively. Although this study suggests that a 12 month cutoff may be used for the PFI, international consensus and other studies have moved towards using a cutoff of six months instead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics and behavior and are referred to as epithelial ovarian cancer (EOC). EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women in the United States. Approximately 75 percent of cases are stage III (spread throughout the peritoneal cavity or involving lymph nodes) or IV (spread to more distant sites).",
"     </li>",
"     <li>",
"      Advanced stage EOC is initially treated with surgical cytoreduction followed by adjuvant therapy. A choice among adjuvant treatments is made based upon the amount of disease remaining after surgery. Patients with &lt;1 cm of disease in any one location are considered to have optimally cytoreduced EOC. All other patients have suboptimally cytoreduced disease.",
"     </li>",
"     <li>",
"      For women with suboptimally cytoreduced EOC, we recommend chemotherapy with a platinum plus taxane combination (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We prefer six cycles of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      administered on day 1 of a 21-day cycle (",
"      <a class=\"graphic graphic_table graphicRef65626 \" href=\"UTD.htm?6/57/7070\">",
"       table 1",
"      </a>",
"      ). Other clinicians use alternative platinum plus taxane combinations. (See",
"      <a class=\"local\" href=\"#H250842535\">",
"       'Platinum and taxane combination therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H760222525\">",
"       'Alternative doses and schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the lack of an overall survival benefit with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in this setting, we suggest the use of a platinum plus taxane combination alone rather than in combination with bevacizumab (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H284998595\">",
"       'Incorporation of angiogenesis inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with optimally cytoreduced EOC, we recommend a combination of intravenous plus intraperitoneal",
"      <span class=\"nowrap\">",
"       (IV/IP)",
"      </span>",
"      chemotherapy rather than intravenous chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For women who are not candidates for IP therapy due to medical comorbidities, borderline performance status, or other clinical reasons, we prefer to administer standard IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H250842013\">",
"       'Intraperitoneal chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with advanced EOC who are not surgical candidates, or women with stage IV disease (histologically confirmed involvement of the lungs or liver), we suggest neoadjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Following three cycles, repeat staging should be performed and those with at least stable disease should proceed with an interval debulking surgery, followed by adjuvant chemotherapy. (See",
"      <a class=\"local\" href=\"#H250841373\">",
"       'Neoadjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following the completion of treatment, we perform a posttreatment evaluation with a history, physical (including pelvic) exam, and CA-125. Imaging such as computed tomography (CT) of the chest, abdomen, and pelvis, may be utilized as well. Following the documentation of a response, patients are monitoring serially with physical examination and tumor marker studies. (See",
"      <a class=\"local\" href=\"#H250841768\">",
"       'Evaluation after chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who attain a clinical complete remission, we suggest observation over the administration of maintenance chemotherapy unless enrolled in a clinical trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1171802\">",
"       'Maintenance chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrence can be detected either serologically using tumor markers (eg, CA-125)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by the development of clinical or radiologic signs of progression. For women who have completed initial chemotherapy, we recommend retreatment based on signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of relapsed EOC and not based on a rising CA-125 alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H1105882#H1105882\">",
"       \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Role of CA-125 surveillance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/1\">",
"      Omura GA, Morrow CP, Blessing JA, et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983; 51:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/2\">",
"      Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994; 55:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/3\">",
"      McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/4\">",
"      du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 Suppl 8:viii7.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Guidelines Version 2.2012: Epithelial ovarian cancer/fallopian tube cancer/ primary peritoneal cancer. file://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (Accessed on November 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/6\">",
"      H&ouml;gberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001; 40:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/7\">",
"      Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/8\">",
"      Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group. Cochrane Database Syst Rev 2000; :CD001418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/9\">",
"      Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18:3084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/10\">",
"      Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/11\">",
"      du Bois A, L&uuml;ck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/12\">",
"      Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/13\">",
"      Bookman MA. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann Oncol 2010; 21 Suppl 7:vii211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/14\">",
"      Dizon DS, Weitzen S, Rojan A, et al. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Gynecol Oncol 2006; 100:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/15\">",
"      Kim HS, Park NH, Chung HH, et al. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn J Clin Oncol 2008; 38:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/16\">",
"      Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006; 98:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/17\">",
"      du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006; 24:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/18\">",
"      Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/19\">",
"      Alberts DS, Marth C, Alvarez RD, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 2008; 109:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/20\">",
"      Aravantinos G, Fountzilas G, Bamias A, et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer 2008; 44:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/21\">",
"      Bolis G, Scarfone G, Raspagliesi F, et al. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 2010; 46:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/22\">",
"      du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28:4162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/23\">",
"      Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010; 102:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/24\">",
"      M&ouml;bus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25:4187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/25\">",
"      McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/26\">",
"      Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/27\">",
"      Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/28\">",
"      Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011; 29:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/29\">",
"      Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/30\">",
"      Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/31\">",
"      Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991; 18:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/32\">",
"      Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006; :CD005340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/33\">",
"      Hess LM, Benham-Hutchins M, Herzog TJ, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007; 17:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/34\">",
"      Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/35\">",
"      Dizon DS, Sill MW, Gould N, et al. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 2011; 123:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/36\">",
"      Deraco M, Kusamura S, Virz&igrave; S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol 2011; 122:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/37\">",
"      Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008; 113:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/38\">",
"      Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 2009; 135:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/39\">",
"      Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/40\">",
"      Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990; 82:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/41\">",
"      Burstein HJ, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 2011; 29:3328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/42\">",
"      Mei L, Chen H, Wei DM, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev 2010; :CD007414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21689/abstract/43\">",
"      Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9:389.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3239 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21689=[""].join("\n");
var outline_f21_11_21689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20367464\">",
"      INITIAL CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H250842527\">",
"      Intravenous chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H250842535\">",
"      - Platinum and taxane combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H760222525\">",
"      Alternative doses and schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H284998595\">",
"      Incorporation of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H250842013\">",
"      Intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284999123\">",
"      - Hyperthermic intraoperative IP chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H250841366\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H250841373\">",
"      Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H250841395\">",
"      In vitro chemosensitivity and resistance assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H250841768\">",
"      EVALUATION AFTER CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1171802\">",
"      MAINTENANCE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H760206841\">",
"      TREATMENT OF RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/57/7070\" title=\"table 1\">",
"      Paclitaxel and carboplatin chemotherapy for EOC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25847?source=related_link\">",
"      Epithelial ovarian cancer: Second look surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/537?source=related_link\">",
"      Intraperitoneal chemotherapy for treatment of ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24472?source=related_link\">",
"      Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_11_21690="Indications for and complications of renal biopsy";
var content_f21_11_21690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for and complications of renal biopsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21690/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21690/contributors\">",
"     William L Whittier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21690/contributors\">",
"     Stephen M Korbet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21690/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/11/21690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/11/21690/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/11/21690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A percutaneous renal biopsy may be obtained for a number of reasons, including establishment of the exact diagnosis, as an aid to determine the nature of recommended therapy or to help decide when treatment is futile, and to ascertain the degree of active (ie, potentially reversible) and chronic (ie, irreversible) changes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The degree of active or chronic changes helps determine prognosis and likelihood of response to treatment. In addition, kidney biopsy can be performed to help assess genetic diseases.",
"   </p>",
"   <p>",
"    It is important to recognize that prognostication based on renal pathology alone may be affected by the sample size (particularly in lesions that are focal in nature) and may not be very accurate in biopsies with few glomeruli (ie, &le;5). The findings in renal biopsy always need to be interpreted in the context of the clinical and laboratory features. Chronic changes (interstitial fibrosis and tubular atrophy), for example, are a sign of the magnitude and duration of prior injury.",
"   </p>",
"   <p>",
"    The following topic review provides an overview of issues relating to percutaneous renal biopsy. Nonpercutaneous renal biopsy techniques are also discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine evaluation of a percutaneous renal biopsy involves examination of the tissue under light, immunofluorescence (and immunoperoxidase in some laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/3\">",
"     3",
"    </a>",
"    ]), and electron microscopy. Each component of the evaluation can provide important diagnostic information. (See appropriate topic reviews for discussions concerning pathologic findings in individual disorders). The routine immunofluorescence examination of biopsy specimens should include (at a minimum) evaluation of IgG, IgM, IgA, C3, C1q, albumin, fibrin, and kappa and lambda immunoglobulin light chains. Special studies, including evaluation of serum Amyloid A deposits, IgG subclasses (IgG1-4), and collagen chains (alpha 3.4 and 5) may be helpful in some cases where available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Justification for the routine application of electron microscopy comes largely from studies in the 1960s and 1970s, which showed that this technique provided substantive diagnostic information beyond that obtained from light microscopy in nearly 50 percent of cases. However, most of these studies were performed at a time when immunofluorescence microscopy was not widely available.",
"   </p>",
"   <p>",
"    To assess the utility of electron microscopy, a study of 288 native renal biopsies performed over a six-month period in 1996 examined the diagnostic findings provided by light, immunofluorescence, and electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/4\">",
"     4",
"    </a>",
"    ]. When viewed in combination with the results from light and immunofluorescence microscopy, electron microscopy provided:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Required diagnostic information in 50 cases &ndash; 21 percent",
"     </li>",
"     <li>",
"      Important confirmatory data in 48 &ndash; 21 percent",
"     </li>",
"     <li>",
"      Additional unrelated findings in eight &ndash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with the results from earlier studies and support the continued use of routine electron microscopy. Diagnoses that commonly require electron microscopy included minimal change disease, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, membranous nephropathy, thin basement membrane disease and Alport syndrome, postinfectious glomerulonephritis, HIV-associated nephropathy, amyloidosis, immunoglobulin deposition diseases, and fibrillary (immunotactoid) glomerulopathy. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications and when biopsy may not be necessary'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS AND WHEN BIOPSY MAY NOT BE NECESSARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for performing a renal biopsy vary among nephrologists, determined in large part by the presenting signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,2,5-7\">",
"     1,2,5-7",
"    </a>",
"    ]. This is an important issue since the following discussion will include a number of settings in which renal biopsy is",
"    <strong>",
"     not indicated",
"    </strong>",
"    , which will avoid the potential risk of bleeding and other complications associated with renal biopsy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The overall rate of native kidney biopsy (in number of procedures per million population [pmp]) varies from over 250 pmp in Australia to less than 75 pmp in the USA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/8\">",
"     8",
"    </a>",
"    ]. The renal biopsy rate is higher in adults than in children. These differences in renal biopsy rate are not driven by differences in the spectrum of renal pathology, but rather by opinions regarding the value of the procedure in diagnosis, prognosis, and therapy. In many academic medical centers, biopsies of the transplanted kidney exceed those performed to diagnose disease in the native kidney.",
"   </p>",
"   <p>",
"    The results of the renal biopsy impact patient care in up to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/5,9-11\">",
"     5,9-11",
"    </a>",
"    ]. However, the utility of the biopsy may differ considerably based upon the indication. Older age per se is not a contraindication to renal biopsy.",
"   </p>",
"   <p>",
"    The following discussion will review the indications for renal biopsy according to the clinical presentation. A review of the causes of the major clinical patterns (eg, nephrotic and nephritic) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H2#H2\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Clinical patterns of glomerular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Isolated glomerular hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with asymptomatic microscopic hematuria (ie, persistent microscopic hematuria with dysmorphic red blood cells, negative \"dipstick\" for proteinuria, normal serum creatinine concentration, and normal blood pressure), the renal biopsy may not alter therapy, as such patients generally have a good prognosis. When biopsies are performed, they typically demonstrate either a normal kidney biopsy or one of three disorders: IgA nephropathy, hereditary nephritis (Alport syndrome), or thin basement membrane disease. Most patients with IgA nephropathy and thin basement membrane disease without proteinuria have a good long-term prognosis and, other than angiotensin converting enzyme inhibitors, there is no clear effective therapy for any of these conditions. However, some patients (such as those with Alport syndrome) may desire a histologic diagnosis for genetic counseling purposes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/2/17445?source=see_link\">",
"     \"Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, a renal biopsy is not routinely performed to establish a specific diagnosis, at least in the United States, unless there is coexisting proteinuria or evidence of renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/6\">",
"     6",
"    </a>",
"    ]. In a prospective study of 276 native renal biopsies, for example, biopsy for isolated hematuria changed a management decision in only 1 of 36 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a biopsy is not performed, ongoing follow-up to monitor for the development of proteinuria or disease progression is warranted. This is particularly true with IgA nephropathy since the majority of patients who are first seen with isolated hematuria have progressive disease (eg, development of proteinuria, hypertension, or renal insufficiency) over many years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal biopsies are not indicated in patients with persistent nonglomerular hematuria; such patients need a thorough urologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Isolated nonnephrotic proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal biopsy generally is",
"    <strong>",
"     not",
"    </strong>",
"    performed in a patient who presents with low-grade proteinuria (less than 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    absence of glomerular hematuria, usually normal renal function, and an absence of clinical or serologic evidence of a systemic disease that can cause glomerulonephritis (eg, systemic lupus erythematosus, vasculitis, or a paraproteinemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .) Some of these patients will have mild primary focal segmental glomerulosclerosis, IgA nephropathy, or membranous nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/13\">",
"     13",
"    </a>",
"    ]; however, immunosuppressive therapy would not be indicated in this setting, since the prognosis with nonnephrotic proteinuria is often excellent. Other patients will have secondary focal segmental glomerulosclerosis as a response to ischemic injury (as in nephrosclerosis) or to nephron loss (as in reflux nephropathy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many nephrologists routinely perform a renal biopsy in patients with somewhat higher degrees of nonnephrotic proteinuria (1 to 2",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    except in the setting where this may be explained by conditions, such as longstanding diabetes mellitus or hypertension. If such a patient is reluctant to undergo biopsy, indications for further encouragement of the patient to consent to the procedure include increasing proteinuria or serum creatinine concentrations, or the new onset of hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsy is performed in most adults and older children with apparently idiopathic nephrotic syndrome (ie, no apparent underlying disease). In this setting, it is likely that one of the three major causes of the idiopathic nephrotic syndrome is present: minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy. The findings on renal biopsy frequently influence therapy in older children and adults. In one report, for example, renal biopsy for nephrotic syndrome in adults influenced the management decision in 86 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/5\">",
"     5",
"    </a>",
"    ]. This is due in part to the presence of an unexpected diagnosis, such as primary (AL) amyloidosis, fibrillary (immunotactoid) glomerulonephritis, or membranous nephropathy with signs of underlying lupus that may occur in the absence of the typical serologic changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H20#H20\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Initial therapy versus renal biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal biopsy is also often indicated in patients with systemic lupus erythematosus since a proliferative glomerulonephritis may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to these indications, there are a variety of patients with the nephrotic syndrome in whom renal biopsy usually",
"    <strong>",
"     not",
"    </strong>",
"    performed at diagnosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with diabetes mellitus for many years in whom the initial manifestation is microalbuminuria that slowly progresses to overt proteinuria over many years. However, nondiabetic renal disease can occur and there are a variety of clinical clues that suggest nondiabetic disease. This issue is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of diabetic nephropathy\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link&amp;anchor=H26#H26\">",
"       \"Overview of diabetic nephropathy\", section on 'Nondiabetic renal disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with nephrotic syndrome that seems, from the history and presence of extrarenal involvement, to be due to primary or secondary amyloidosis, which can be diagnosed by less invasive tissue biopsy (such as abdominal fat pad or rectal biopsy). In contrast, a biopsy is usually performed in patients with active lupus nephritis to determine the type of disease that is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link&amp;anchor=H1666048#H1666048\">",
"       \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\", section on 'Choosing a biopsy site'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link&amp;anchor=H26#H26\">",
"       \"Overview of diabetic nephropathy\", section on 'Nondiabetic renal disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link\">",
"       \"Indications for renal biopsy in patients with lupus nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children under the age of six years with the acute onset of nephrotic syndrome, since over 90 percent have minimal change disease. Other causes of nephrotic syndrome may occur in older children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H9#H9\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients (children and adults) with relapse of steroid-sensitive nephrotic syndrome following the cessation of appropriate immunosuppressive therapy, such as frequently relapsing minimal change disease. Patients with nephrotic syndrome that may be related to a drug such as a nonsteroidal antiinflammatory drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , gold, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      . The time to recovery after cessation of the offending drug can be as long as several years, as seen with nephrotic syndrome due to penicillamine or gold. Renal biopsy may be performed at diagnosis if the nephrotic syndrome is accompanied by moderate to severe acute kidney injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology, clinical features, and diagnosis of minimal change disease in adults\", section on 'Drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link&amp;anchor=H12#H12\">",
"       \"Causes and diagnosis of membranous nephropathy\", section on 'Drugs, particularly penicillamine and gold'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link&amp;anchor=H3#H3\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\", section on 'Acute interstitial nephritis and nephrotic syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link&amp;anchor=H5#H5\">",
"       \"Renal toxicity of lithium\", section on 'Nephrotic syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with overt (already diagnosed) malignancy. The major associations are membranous nephropathy with solid tumors and less often a hematologic malignancy such was chronic lymphocytic leukemia; and minimal change disease with lymphoma or leukemia. In these settings, the nephrotic syndrome often resolves with effective treatment of the malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link&amp;anchor=H16#H16\">",
"       \"Causes and diagnosis of membranous nephropathy\", section on 'Malignancy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link&amp;anchor=H11#H11\">",
"       \"Etiology, clinical features, and diagnosis of minimal change disease in adults\", section on 'Neoplasms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with massive obesity who have slowly increasing proteinuria over time that is often subnephrotic rather than the abrupt onset of nephrotic syndrome. These patients usually have secondary focal segmental glomerulosclerosis (FSGS, called obesity-related glomerulopathy) or diabetic nephropathy. The proteinuria in patients with secondary FSGS often improves with weight loss. In contrast, we would perform a renal biopsy in obese patients with nephrotic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H19#H19\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Severe obesity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute nephritic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute nephritic syndrome &mdash; hematuria, cellular casts, proteinuria, and frequently hypertension and renal insufficiency &mdash; is often caused by a systemic disease that requires a renal biopsy to establish the diagnosis and guide treatment. However, there are situations in which the initiation of therapy is required while awaiting the renal biopsy. Examples include microscopic polyangiitis, granulomatosis with polyangiitis (Wegener's), or anti-GBM antibody disease. These are disorders that are associated with rapidly progressive glomerulonephritis and, in the appropriate clinical setting, are suggested serologically by the presence of circulating antineutrophil cytoplasmic antibodies (ANCA) or anti-GBM antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason for a biopsy is variable in lupus nephritis. Patients with acute renal insufficiency and an active urine sediment may have any number of lesions and require a renal biopsy to establish a diagnosis, determine prognosis, and guide therapy. A repeat biopsy may also be performed for late progression of the disease to distinguish between active lupus (which may require immunosuppressive therapy) and scarring of previous inflammatory injury (which may warrant antihypertensive therapy with an angiotensin converting enzyme inhibitor). These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glomerulonephritis also may be associated with hepatitis C or B virus or with positive cultures for fungi or parasites or a chronic bacterial abscess. The authors and reviewers of this topic",
"    <strong>",
"     would",
"    </strong>",
"    perform a renal biopsy in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"     \"Renal disease associated with hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal biopsy is usually",
"    <strong>",
"     not",
"    </strong>",
"    performed in patients with a presumptive diagnosis of poststreptococcal glomerulonephritis based upon the clinical history of recent pharyngitis or skin infection and a positive streptozyme test",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    throat or skin culture for group A beta-hemolytic streptococcal infection. Resolution of PSGN is usually rapid if there is resolution of the infection. A diuresis typically begins within one week and the serum creatinine returns to the previous baseline in three to four weeks. Other causes of glomerulonephritis should be considered and renal biopsy performed if there are recurrent episodes of hematuria, which is suggestive of IgA nephropathy, persistent hypocomplementemia at six weeks after appropriate therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a progressive increase in serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link&amp;anchor=H15#H15\">",
"     \"Poststreptococcal glomerulonephritis in children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal biopsy is also",
"    <strong>",
"     not",
"    </strong>",
"    usually performed in patients with glomerulonephritis associated with endocarditis or shunt nephritis in whom control of the infection usually leads to rapid resolution of the renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=see_link\">",
"     \"Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Unexplained acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of acute renal failure &mdash; prerenal disease, acute tubular necrosis, and urinary tract obstruction &mdash; can be diagnosed clinically without renal biopsy. Biopsy is indicated in those settings in which the diagnosis is uncertain, as may sometimes be the case with acute interstitial nephritis secondary to drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/6\">",
"     6",
"    </a>",
"    ]. By comparison, patients with small kidneys or slowly progressive chronic renal failure over a period of years are generally not biopsied since there is little likelihood of finding a treatable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREBIOPSY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to a percutaneous renal biopsy, a history, physical examination, and selected laboratory tests should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/14\">",
"     14",
"    </a>",
"    ]. The skin overlying the biopsy site should be free of signs of infection, and the blood pressure should be well-controlled. The patient should also be able to follow simple directions.",
"   </p>",
"   <p>",
"    Recommended laboratory tests include a complete biochemical profile, complete blood count, platelet count, prothrombin time, partial thromboplastin time, and bleeding time, if available. A bleeding diathesis, if discovered, should be appropriately evaluated and treated prior to undertaking a renal biopsy.",
"   </p>",
"   <p>",
"    The value of routine measurement of the bleeding time continues to be debated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. A position paper from the college of American Pathologists and American Society of Clinical Pathologists reported that the bleeding time lacked clinical benefit to predict surgical bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, extrapolation of use of the bleeding time for an open surgical procedure, in which direct hemostasis can be achieved, to a closed procedure, such as the percutaneous renal biopsy, is unclear. This is an important issue because patients with CKD may have an elevated bleeding time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and, thus, the bleeding time may be of value in this population. Although there are no randomized prospective studies evaluating the use of the bleeding time in the setting of a percutaneous renal biopsy, observational studies have demonstrated a bleeding complication rate that is three to five times higher in those patients with abnormal bleeding times [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Other series, however, report no increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/16,24\">",
"     16,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link&amp;anchor=H7#H7\">",
"     \"Preoperative assessment of hemostasis\", section on 'Bleeding time'",
"    </a>",
"    .) Other tests to determine platelet function may prove to be useful but have not been tested in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A renal ultrasound should precede the biopsy to assess the size of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    presence of any anatomic abnormalities that may preclude the performance of a percutaneous biopsy (for example, solitary kidney, polycystic kidney, malpositioned or horseshoe kidney, small echogenic kidneys, or hydronephrosis). The renal ultrasound is often performed at the time of the biopsy (unless it is done under CT guidance or as an open procedure by a surgeon).",
"   </p>",
"   <p>",
"    Since bleeding is the principal complication of renal biopsy, the evaluation should focus upon any evidence for a bleeding diathesis and the recent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or nonsteroidal antiinflammatory drugs. To help ensure normal coagulation, patients should refrain from taking antiplatelet or antithrombotic agents (eg, aspirin, omega-3 fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/25\">",
"     25",
"    </a>",
"    ], GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , and nonsteroidal antiinflammatory drugs) for at least one to two weeks prior to a scheduled elective biopsy and remain off of them for one to two weeks after the biopsy. Patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    should have this stopped the day prior to the procedure. The approach to patients on long-term anticoagulation is discussed below.",
"   </p>",
"   <p>",
"    The incidence of clinically significant bleeding is minimized if these coagulation tests are normal and in the absence of significant anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/20\">",
"     20",
"    </a>",
"    ]. If a diagnosis is urgent in patients with uremia or an abnormal bleeding time, a renal biopsy may be performed as an open procedure or after the bleeding diathesis is corrected using a variety of possible measures, such as administration of fresh frozen plasma or with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP). When the bleeding time is elevated and not related to medications known to impair platelet function, we give desmopressin 0.3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    intravenously and repeat the bleeding time in one half hour. If the bleeding time normalizes, we proceed with a percutaneous renal biopsy. However, studies caution that even after correcting the bleeding time with the use of desmopressin, the risk of bleeding may still be higher than if the bleeding time had been normal at the beginning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. If the bleeding time remains elevated after giving desmopressin, we refer the patient for a nonpercutaneous renal biopsy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Nonpercutaneous renal biopsy techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RELATIVE CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous renal biopsy for the detection of primary renal disease is generally not pursued in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small hyperechoic kidneys (less than 9 cm), which are generally indicative of chronic irreversible disease",
"     </li>",
"     <li>",
"      Solitary native kidney",
"     </li>",
"     <li>",
"      Multiple, bilateral cysts or a renal tumor",
"     </li>",
"     <li>",
"      Uncorrectable bleeding diathesis",
"     </li>",
"     <li>",
"      Severe hypertension, which cannot be controlled with antihypertensive medications",
"     </li>",
"     <li>",
"      Hydronephrosis",
"     </li>",
"     <li>",
"      Active renal or perirenal infection",
"     </li>",
"     <li>",
"      Anatomic abnormalities of the kidney which may increase risk (see above)",
"     </li>",
"     <li>",
"      Skin infection over the biopsy site",
"     </li>",
"     <li>",
"      An uncooperative patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While some contraindications may be considered relative in nature, absolute contraindications for the performance of a percutaneous native kidney renal biopsy were defined in a position paper by the Health and Public Policy Committee of the American College of Physicians in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/26\">",
"     26",
"    </a>",
"    ]. These include uncontrolled severe hypertension, uncontrollable bleeding diathesis, uncooperative patient, and a solitary native kidney. The absolute contraindication of biopsying a solitary kidney has been challenged due to the improved safety associated with newer imaging and biopsy techniques. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Solitary native kidney'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Advanced age is not a contraindication to the procedure. Several studies have shown that percutaneous renal biopsy can be performed safely and revealed unanticipated diagnoses in 15 to 33 percent of cases in the elderly population (over age 60) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Even among the very old (over age 80), renal biopsy may provide valuable diagnostic and prognostic data [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy is also not a contraindication to the procedure. Several series have shown complication rates of the percutaneous approach in the prone position similar those reported in nonpregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, despite the safety, as there is always potential for maternal-fetal morbidity, consideration should be given to avoid or defer the procedure until the postpartum period unless it may change management prior to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patients on chronic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of issues that must be considered in patients on chronic anticoagulation in whom a renal biopsy is being considered. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether the renal biopsy is essential for diagnosis, prognosis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      management",
"     </li>",
"     <li>",
"      The indications for chronic anticoagulation and risk of thrombosis if anticoagulation is temporarily stopped (eg, venous versus arterial thrombosis, mechanical heart valve).",
"     </li>",
"     <li>",
"      The risk for bleeding after the renal biopsy. Factors other than anticoagulation that increase the risk of bleeding post-biopsy include the level of kidney function (and associated platelet dysfunction), anemia, and blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Bleeding'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the management of patients chronically anticoagulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    must be individualized, often in consultation with hematology and cardiology, as appropriate. A full discussion of the relevant issues is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a general guide concerning the management of such patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to allow the INR to drift below 1.5, or reverse it with vitamin K if the biopsy must be performed urgently. Whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is required prior to the biopsy once the INR falls below 2, and after the biopsy until oral anticoagulation is restarted, depends upon the perceived risk of thrombosis or embolism (eg, type of event, and frequency and remoteness of prior events). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Thrombotic risk if anticoagulation is stopped'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who require intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , it should be stopped for at least six hours prebiopsy to allow the PTT to normalize, and if possible, should not be resumed for at least 12 to 24 hours. In our opinion, withholding heparin for a more prolonged period of up to one week is preferred, unless the thrombotic risk outweighs the bleeding risk. Although most clinically significant bleeding is recognized in the first 12 to 24 hours post-biopsy, bleeding may occur up to several days after the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients on heparin should be closely monitored for signs of bleeding (vital signs, serial hematocrit).",
"     </li>",
"     <li>",
"      Most clinicians would resume oral anticoagulation approximately seven days post-biopsy if there is no evidence of clinically significant bleeding as determined in part by serial monitoring of hemoglobin or hematocrit.",
"     </li>",
"     <li>",
"      For all patients, but particularly those with an increased risk of bleeding, we suggest controlling blood pressure before and after the biopsy to a goal of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An open or, if available, transjugular renal biopsy can be considered if the percutaneous approach is not feasible. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Open renal biopsy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Transjugular renal biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Solitary native kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;A solitary native kidney has been considered an absolute contraindication to percutaneous biopsy, because of the concern that marked bleeding may lead to nephrectomy and loss of all of the patient's functioning renal mass. A surgically performed, open renal biopsy has been the procedure of choice in this setting.",
"   </p>",
"   <p>",
"    Percutaneous renal biopsy of a solitary kidney has been performed successfully in a few selected cases, and it has been suggested that the risk of surgery and nephrectomy with percutaneous biopsy is, as noted below, so low that it may be less than the risk of general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,38,39\">",
"     1,38,39",
"    </a>",
"    ]. However, the experience with this practice is too limited to recommend it safely for widespread practice. Thus, we recommend the use of nonpercutaneous techniques in patients with solitary kidneys who require biopsy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Nonpercutaneous renal biopsy techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should provide informed consent for the biopsy. Possible allergy to local anesthetics and iodine containing solutions should be elicited. Just prior to the procedure, peripheral intravenous access is placed and the patient is usually placed prone with a pillow under the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/14\">",
"     14",
"    </a>",
"    ]. If the patient is pregnant or very obese, the biopsy can be performed in the seated, lateral decubitus, or supine anterolateral position [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/31,32,40\">",
"     31,32,40",
"    </a>",
"    ]. Some anxious patients may require mild sedation, but when prescribing sedatives, caution should be taken and side effects considered.",
"   </p>",
"   <p>",
"    Percutaneous renal biopsy is usually performed under ultrasonic guidance with local anesthesia (usually 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    hydrochloride) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. Ultrasonography can localize the desired lower pole site (at which the risk of puncturing a major vessel is minimized), determine renal size, and detect the unexpected presence of cysts that might necessitate using the contralateral kidney.",
"   </p>",
"   <p>",
"    After the lower pole is localized, a skin mark is made to identify where the biopsy needle will be inserted. The site is subsequently prepped and anesthetized. Under ultrasound guidance, a spinal needle is then used to locate the capsule of the lower pole and to provide anesthesia for the biopsy needle tract.",
"   </p>",
"   <p>",
"    After a small skin incision is made to facilitate passage, real time ultrasonography is most commonly used to guide the biopsy needle directly into the lower pole [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/14,41\">",
"     14,41",
"    </a>",
"    ]. This somewhat more cumbersome procedure has the advantage of direct visualization of the location of the needle as the core of tissue is obtained.",
"   </p>",
"   <p>",
"    The use of real-time ultrasound has been compared to the \"blind\" approach (using ultrasound for localization only). A retrospective study demonstrated a higher diagnostic yield (100 percent versus 84 percent) as well as a lower major hemorrhagic complication rate (0 percent versus 11 percent) in the group using real-time ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/42\">",
"     42",
"    </a>",
"    ]. We therefore suggest the use of real-time ultrasonography rather than ultrasonography for localization only.",
"   </p>",
"   <p>",
"    A CT scan is an alternative when the kidneys cannot be well visualized, as with marked obesity or small echogenic kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of different biopsy needles are available, including manual needles (TruCut disposable, Franklin-Silverman, Vim-Silverman) and automated spring-loaded biopsy needles [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,2,4,41,43-45\">",
"     1,2,4,41,43-45",
"    </a>",
"    ]. The choice of biopsy needle is largely one of individual preference.",
"   </p>",
"   <p>",
"    Several studies have compared the adequacy and safety of different needle gauges and types. The automated needles and larger gauge needles (14 and 16 gauge compared as compared with 18 gauge) have provided more glomeruli per core and per biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/43,46-48\">",
"     43,46-48",
"    </a>",
"    ]. There is no difference in complication rate between a manual needle and an automatic needle of the same gauge [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective single-center study of 471 patients reported no difference in frequency of complications or number of glomeruli obtained between automated needles of 14 gauge compared with 16 gauge [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, a nationwide registry study in Norway of 9288 biopsies revealed no difference in complications between 14 and 16 gauge needles, although there was a higher rate of complications with 18 gauge needles. In addition, there were more glomeruli per biopsy with use of either of the larger needles (14 or 16 gauge) as compared with 18 gauge needles [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/49\">",
"     49",
"    </a>",
"    ]. However, a meta-analysis of 34 retrospective (N = 21) and prospective (N = 13) studies, including 9474 biopsies, revealed an increased need for erythrocyte transfusion in studies using a 14 gauge as compared with either 16 or 18 gauge [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with kidney transplants, a prospective randomized study evaluated automated needles of varying sizes: 14 gauge, 16 gauge, and 18 gauge. The diagnostic yield was the greatest with the 14 gauge needle. The complication rates were no different between the three groups; however, more pain was associated with the 14 gauge needle [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining the optimal depth to advance the biopsy needle using the patient's height and weight has been shown by one group of investigators to reduce complication rates and improve biopsy adequacy, however the clinical utility of this approach in a general population has not been shown [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To optimize safety, adequacy, and patient comfort, we recommend the use of either a 14 or 16 gauge spring-loaded needle with real time ultrasonic guidance for native and transplant kidney biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obtaining two cores of renal tissue is generally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,2,14\">",
"     1,2,14",
"    </a>",
"    ]. However, the quantity of tissue required varies with the likely diagnosis. As an example, the distinction of focal (arbitrarily defined as fewer than 50 percent of glomeruli affected on light microscopy) from diffuse proliferative lupus nephritis may require up to 100 glomeruli to make the diagnosis with a reasonable degree of statistical certainty [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1\">",
"     1",
"    </a>",
"    ]; obtaining this quantity of renal tissue is rare with percutaneous biopsy and sampling error may therefore explain the seeming variability in clinical outcome in patients with focal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link&amp;anchor=H5#H5\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\", section on 'Focal proliferative LN (class III)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is the primary complication of renal biopsy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54874 \" href=\"UTD.htm?15/50/16175\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Postbiopsy bleeding can occur at three sites: (1) into the collecting system, leading to microscopic or gross hematuria and possible ureteral obstruction; (2) underneath the renal capsule, leading to pressure tamponade and pain; or (3) into the perinephric space, leading to hematoma formation and a possibly large fall in hematocrit. Rarely, severe bleeding may occur due to puncture of the renal artery, aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/53\">",
"     53",
"    </a>",
"    ], or venous collaterals (in patients with renal vein thrombosis). Most clinically significant bleeding is recognized within 12 to 24 hours of the biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously mentioned, the incidence of bleeding is minimized with normal partial thromboplastin time, prothrombin time, platelet count, and bleeding time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/20\">",
"     20",
"    </a>",
"    ]. Additional clinical risk factors for bleeding include hypertension, reduced glomerular filtration rate, anemia, older age, the use of a larger (14 gauge) biopsy needle, and when biopsy is performed in a patient with acute as opposed to chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/14,36,37,50,54\">",
"     14,36,37,50,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of 34 retrospective and prospective studies, including 9474 adults who underwent native kidney biopsy using real-time ultrasonic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/50\">",
"     50",
"    </a>",
"    ], the approximate incidence of the different bleeding complications was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient macroscopic hematuria (3.5 percent)",
"     </li>",
"     <li>",
"      Requirement for erythrocyte transfusion (0.9 percent)",
"     </li>",
"     <li>",
"      Requirement for angiographic intervention to control bleeding (0.6 percent)",
"     </li>",
"     <li>",
"      Requirement for nephrectomy to control bleeding (0.01 percent)",
"     </li>",
"     <li>",
"      Death (0.02 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rates of bleeding complications in this review varied according to certain risk factors. The rate of requiring erythrocyte transfusion, which was 0.9 percent overall, was on average significantly higher in patients with the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic blood pressure greater than or equal to 130 mmHg (1.4 versus 0.1 percent)",
"     </li>",
"     <li>",
"      Serum creatinine greater than or equal to 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      (2.1 versus 0.4 percent)",
"     </li>",
"     <li>",
"      Hemoglobin concentration less than 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (2.6 versus 0.5 percent)",
"     </li>",
"     <li>",
"      Age over 40 years (1 versus 0.2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior reports suggested an increased risk of complication in certain disorders, such as autoimmune disease, end-stage renal disease, acute tubular necrosis, and amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/22,24,54\">",
"     22,24,54",
"    </a>",
"    ]. However, more subsequent studies did not show an increased in risk of hemorrhagic complications among patients with systemic amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/55\">",
"     55",
"    </a>",
"    ] or monoclonal gammopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of bleeding may be decreased by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) prior to biopsy. This was shown in a single-center randomized placebo-controlled trial in which 162 patients were randomly assigned to receive either desmopressin or placebo prior to an ultrasound-guided biopsy of a native kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/57\">",
"     57",
"    </a>",
"    ]. All patients were low risk for bleeding: all had an estimated glomerular filtration rate (eGFR) greater than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, blood pressure less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg and normal coagulation parameters including normal bleeding times.",
"   </p>",
"   <p>",
"    Fewer patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    group had a hematoma detected on postbiopsy screening ultrasound (13.7 versus 30.5 percent in the placebo group). The hematomas were clinically silent as there was no difference between groups in hemoglobin following the biopsy, and no patient in either group had gross hematuria or required a transfusion or intervention.",
"   </p>",
"   <p>",
"    The clinical benefit of preventing an ultrasound-detected hematoma that causes no symptoms is not clear; in addition this study was not powered to detect adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , such as thrombosis or hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/58\">",
"     58",
"    </a>",
"    ]. We suggest",
"    <strong>",
"     not",
"    </strong>",
"    using desmopressin prior to biopsy in patients at low risk for bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potential complications of renal biopsy that may or may not be related to bleeding include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain lasting more than 12 hours in 4 percent; this problem may be due to ureteral obstruction from a blood clot in patients with gross hematuria or to stretching of the renal capsule by a subcapsular hematoma.",
"     </li>",
"     <li>",
"      Arteriovenous fistulas form in up to 18 percent of cases due to damage to the walls of an adjacent artery and vein (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59858 \" href=\"UTD.htm?10/35/10800\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,59\">",
"       1,59",
"      </a>",
"      ]. Postbiopsy fistulas are usually clinically silent and resolve spontaneously over one to two years. Symptomatic fistulas, causing hematuria, hypotension, or high-output heart failure, are now rare. The diagnosis can be established by color Doppler ultrasonography or arteriography [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/59\">",
"       59",
"      </a>",
"      ]. Either transcatheter arterial embolization or surgical ligation can be used to close a symptomatic fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another rare complication is chronic hypertension due to the \"Page kidney\" [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. In this setting, pressure-induced ischemia from a large subcapsular hematoma can lead to persistent activation of the renin-angiotensin system.",
"     </li>",
"     <li>",
"      Perirenal soft tissue infection may occur in 0.2 percent of cases, most often in patients with active parenchymal renal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,63\">",
"       1,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, puncture of the liver, pancreas, or spleen may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTPROCEDURE OBSERVATION AND TIMING OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be supine for four to six hours and then remain at bed rest overnight. To help detect bleeding and other complications, vital signs are closely monitored, and the urinalysis and complete blood count are obtained at various time points postbiopsy. To minimize the risk of bleeding, blood pressure should be well controlled (goal",
"    <span class=\"nowrap\">",
"     &lt;140/90",
"    </span>",
"    mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important question in this era of cost-containment is what the optimal period of observation after renal biopsy is. This is determined primarily by the time course of complications, particularly bleeding.",
"   </p>",
"   <p>",
"    One report best addressed this issue in 750 native kidney biopsies in adults with a normal bleeding time, no evidence of coagulopathy, and a stable blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/37\">",
"     37",
"    </a>",
"    ]. The biopsies were performed with real-time ultrasonic guidance and the last 523 used an automated biopsy needle. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall major complication rate (bleeding severe enough to require a transfusion or invasive procedure, septicemia, acute renal obstruction or failure, or death) was 6.4 percent, while the rate of minor complications was 6.6 percent.",
"     </li>",
"     <li>",
"      Clinical recognition of a major complication occurred within 4, 8, 12, and 24 hours among 38, 67, 89, and 91 percent of patients, respectively. A similar time course was noted with minor events.",
"     </li>",
"     <li>",
"      Observation for eight hours or less would have missed 33 percent of complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was concluded that observation for 24 hours was optimal, with more than 90 percent of major complications being identified within this period. Thus, most patients should be observed overnight with monitoring of vital signs and a repeat hematocrit in the morning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/20,37,64\">",
"     20,37,64",
"    </a>",
"    ]. However, in low risk patients (eg, serum creatinine concentration &lt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [221",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    blood pressure",
"    <span class=\"nowrap\">",
"     &lt;140/90",
"    </span>",
"    mmHg, and no evidence of coagulopathy), a shorter observation period has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/19,36,65\">",
"     19,36,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identifying patients that are at low risk of complication is of interest. One study assessed the predictive value of ultrasonography findings one hour after the biopsy in determining the post-biopsy clinical course. The ultrasound findings of a hematoma at one hour had a positive predictive value of only 43 percent but a negative predictive value of 95 percent for the development of a complication. Thus, while the presence of a hematoma was not predictive of a complicated clinical course, a negative ultrasound was highly predictive of an uncomplicated post-biopsy course [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study evaluated the predictive value of an initial six-hour hematocrit with respect to the hematocrit at 24 hours in patients undergoing percutaneous renal biopsy of transplant and native kidneys. The authors found that in patients observed in the hospital for 24 hours, a linear correlation of the hematocrit at six hours to the hematocrit at 24 hours existed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on our experience and published literature, we would recommend observing the patients for at least 12 hours and optimally up to 24 hours in the hospital at bedrest after biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONPERCUTANEOUS RENAL BIOPSY TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Open renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open (surgical) renal biopsy (or a modified open biopsy done under local anesthesia) should be considered in three settings: (1) when there is an uncorrectable bleeding diathesis, in which a transjugular biopsy is another alternative (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Transjugular renal biopsy'",
"    </a>",
"    below); (2) when there is a solitary kidney; and (3) after failed attempts at percutaneous biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/1,67,68\">",
"     1,67,68",
"    </a>",
"    ]. A large core or wedge of renal cortex can usually be obtained, the incidence of severe bleeding is very low, and mortality is rare. Other relatively minor postoperative complications can occur, including fever, atelectasis, and ileus. In addition, an open biopsy under general anesthesia is associated with a longer hospital stay and a larger surgical scar.",
"   </p>",
"   <p>",
"    Open renal biopsy has also been suggested in intensive care unit patients who are being mechanically ventilated. Even in this setting, however, it is possible to perform a percutaneous renal biopsy with portable ultrasonic guidance and the patient prone and being ventilated manually with an ambu bag [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laparoscopic renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic renal biopsy is advocated by some investigators as a viable alternative to open renal biopsy among patients unable or unwilling to undergo percutaneous renal biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. In one series of 32 patients who underwent laparoscopy for a variety of indications, all biopsies were successful and associated with minimal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/70\">",
"     70",
"    </a>",
"    ]. Another series of 21 patients provided similar results, suggesting that this may be a safe and effective alternative to the open renal biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Transjugular renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another technique is transjugular renal biopsy. This procedure is generally performed by an interventionalist in the angiography suite and requires a small amount of intravenous contrast.",
"   </p>",
"   <p>",
"    The risk of perinephric bleeding is theoretically reduced since the renal capsule is not intentionally penetrated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. In centers with experience, the complication rate of this technique is similar to the percutaneous approach [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. However, intrarenal bleeding due to arterial trauma may still occur, and some centers have reported high rates of bleeding due to capsular perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/75,76,78\">",
"     75,76,78",
"    </a>",
"    ]. Contrast-induced nephropathy has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/79\">",
"     79",
"    </a>",
"    ]. Another limitation of the procedure is that obtaining adequate tissue for establishing a diagnosis ranges from only 73 to 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major indication for this modality is an uncorrectable clotting disorder; other indications include the requirement for combined liver or heart and kidney biopsy, morbid obesity, or a single kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/74-78,80-83\">",
"     74-78,80-83",
"    </a>",
"    ]. Some have also performed simultaneous transjugular renal biopsy and hemodialysis catheter placement in patients with dialysis-dependent acute renal failure in whom a histologic diagnosis may alter patient management [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications to a transjugular renal biopsy include bilateral internal jugular vein thrombosis, allergy to contrast media, and the lack of experienced clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/11/21690/abstract/81\">",
"     81",
"    </a>",
"    ]. The greater cost in time, personnel, and radiologic guidance make this procedure impractical for routine renal biopsy, but may be an option in selected circumstances when the appropriate expertise is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=see_link\">",
"       \"Patient information: Renal (kidney) biopsy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"       \"Patient information: The nephrotic syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/62/12257?source=see_link\">",
"       \"Patient information: IgA nephropathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A percutaneous renal biopsy may be obtained to establish a diagnosis, help guide therapy, and ascertain the degree of active and chronic changes. The routine evaluation of a percutaneous renal biopsy involves examination of the tissue under light, immunofluorescence, and electron microscopy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for performing a renal biopsy vary among nephrologists, being determined in part by the presenting signs and symptoms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with the nephrotic syndrome, a biopsy is usually performed in those with lupus nephritis to determine the type of disease that is present. We also usually perform a biopsy in patients with the nephrotic syndrome and no evidence of systemic disease both to determine treatment and to occasionally make an unexpected diagnosis.",
"     </li>",
"     <li>",
"      The acute nephritic syndrome is often caused by a systemic disease that requires a renal biopsy to establish the diagnosis and guide treatment. Even in the absence of a systemic disease, the acute nephritic syndrome often requires a biopsy to ascertain a diagnosis and direct treatment.",
"     </li>",
"     <li>",
"      Among patients with unexplained acute renal failure, a biopsy is indicated in those settings in which the diagnosis is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with isolated glomerular hematuria, a renal biopsy is NOT routinely performed to establish a specific diagnosis, at least in the United States, unless there is evidence of progressive disease such as increasing proteinuria or a rising serum creatinine concentration.",
"     </li>",
"     <li>",
"      A renal biopsy is also generally",
"      <strong>",
"       not",
"      </strong>",
"      performed in a patient who presents with low-grade proteinuria (less than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      the absence of glomerular hematuria, usually normal renal function, and an absence of clinical or serologic evidence of a systemic disease that can cause glomerulonephritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications and when biopsy may not be necessary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to a percutaneous renal biopsy, a history, physical examination, and selected laboratory tests should be performed. Recommended laboratory tests include a complete biochemical profile, complete blood count, platelet count, prothrombin time, partial thromboplastin time, and bleeding time, if available. There are a number of relative contraindications to the performance of a percutaneous renal biopsy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prebiopsy evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Relative contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous renal biopsy is usually performed under ultrasonic guidance with local anesthesia. We suggest the use of real-time ultrasonography rather than the blind approach in which ultrasound is used for localization only (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). To optimize safety, adequacy, and patient comfort, we recommend the use of a spring-loaded needle for native kidney biopsies rather than a manual needle (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For native kidney biopsies, we usually use a 14 gauge spring-loaded needle and try to obtain two cores of renal tissue. Bleeding is the primary complication of renal biopsy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After a percutaneous renal biopsy, we suggest observing the patients for at least 12 hours (and optimally up to 24 hours) in the hospital at bedrest (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Postprocedure observation and timing of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpercutaneous renal biopsies are indicated in settings in which a percutaneous renal biopsy cannot be performed. These techniques include an open, laparoscopic, and transjugular renal biopsy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonpercutaneous renal biopsy techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/1\">",
"      Madaio MP. Renal biopsy. Kidney Int 1990; 38:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/2\">",
"      Appel, GB. Renal biopsy: How effective, what technique, and how safe. J Nephrol 1993; 6:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/3\">",
"      M&ouml;lne J, Breimer ME, Svalander CT. Immunoperoxidase versus immunofluorescence in the assessment of human renal biopsies. Am J Kidney Dis 2005; 45:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/4\">",
"      Haas M. A reevaluation of routine electron microscopy in the examination of native renal biopsies. J Am Soc Nephrol 1997; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/5\">",
"      Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/6\">",
"      Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis 2000; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/7\">",
"      Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/8\">",
"      Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant 2001; 16:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/9\">",
"      Pfister, M, Jakob, S, Frey, FJ, et al. Judgment analysis in clinical nephrology. Am J Kidney Dis 1999; 9:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/10\">",
"      Cohen AH, Nast CC, Adler SG, Kopple JD. Clinical utility of kidney biopsies in the diagnosis and management of renal disease. Am J Nephrol 1989; 9:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/11\">",
"      McGregor DO, Lynn KL, Bailey RR, et al. Clinical audit of the use of renal biopsy in the management of isolated microscopic hematuria. Clin Nephrol 1998; 49:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/12\">",
"      Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/13\">",
"      Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/14\">",
"      Korbet SM. Percutaneous renal biopsy. Semin Nephrol 2002; 22:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/15\">",
"      Mattix H, Singh AK. Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? Curr Opin Nephrol Hypertens 1999; 8:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/16\">",
"      Stiles KP, Hill C, LeBrun CJ, et al. The impact of bleeding times on major complication rates after percutaneous real-time ultrasound-guided renal biopsies. J Nephrol 2001; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/17\">",
"      Whittier WL, Korbet SM. Renal biopsy: update. Curr Opin Nephrol Hypertens 2004; 13:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/18\">",
"      Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/19\">",
"      Lin WC, Yang Y, Wen YK, Chang CC. Outpatient versus inpatient renal biopsy: a retrospective study. Clin Nephrol 2006; 66:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/20\">",
"      Nass K, O'Neill WC. Bedside renal biopsy: ultrasound guidance by the nephrologist. Am J Kidney Dis 1999; 34:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/21\">",
"      Diaz-Buxo JA, Donadio JV Jr. Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. Clin Nephrol 1975; 4:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/22\">",
"      Stratta P, Canavese C, Marengo M, et al. Risk management of renal biopsy: 1387 cases over 30 years in a single centre. Eur J Clin Invest 2007; 37:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/23\">",
"      Waldo B, Korbet SM, Freimanis MG, Lewis EJ. The value of post-biopsy ultrasound in predicting complications after percutaneous renal biopsy of native kidneys. Nephrol Dial Transplant 2009; 24:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/24\">",
"      Manno C, Strippoli GF, Arnesano L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 2004; 66:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/25\">",
"      Berliner AR, Fine DM. There&rsquo;s something fishy about this bleeding. NDT Plus 2011; 4:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/26\">",
"      Clinical competence in percutaneous renal biopsy. Health and Public Policy Committee. American College of Physicians. Ann Intern Med 1988; 108:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/27\">",
"      Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000; 35:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/28\">",
"      Kohli HS, Jairam A, Bhat A, et al. Safety of kidney biopsy in elderly: a prospective study. Int Urol Nephrol 2006; 38:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/29\">",
"      Uezono S, Hara S, Sato Y, et al. Renal biopsy in elderly patients: a clinicopathological analysis. Ren Fail 2006; 28:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/30\">",
"      Moutzouris DA, Herlitz L, Appel GB, et al. Renal biopsy in the very elderly. Clin J Am Soc Nephrol 2009; 4:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/31\">",
"      Packham D, Fairley KF. Renal biopsy: indications and complications in pregnancy. Br J Obstet Gynaecol 1987; 94:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/32\">",
"      Chen HH, Lin HC, Yeh JC, Chen CP. Renal biopsy in pregnancies complicated by undetermined renal disease. Acta Obstet Gynecol Scand 2001; 80:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/33\">",
"      Kuller JA, D'Andrea NM, McMahon MJ. Renal biopsy and pregnancy. Am J Obstet Gynecol 2001; 184:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/34\">",
"      Lindheimer MD, Davison JM. Renal biopsy during pregnancy: 'to b . . . or not to b . . .?'. Br J Obstet Gynaecol 1987; 94:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/35\">",
"      Day C, Hewins P, Hildebrand S, et al. The role of renal biopsy in women with kidney disease identified in pregnancy. Nephrol Dial Transplant 2008; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/36\">",
"      Shidham GB, Siddiqi N, Beres JA, et al. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton) 2005; 10:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/37\">",
"      Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol 2004; 15:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/38\">",
"      Mendelssohn DC, Cole EH. Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys. Am J Kidney Dis 1995; 26:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/39\">",
"      Schow DA, Vinson RK, Morrisseau PM. Percutaneous renal biopsy of the solitary kidney: a contraindication? J Urol 1992; 147:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/40\">",
"      Gesualdo L, Cormio L, Stallone G, et al. Percutaneous ultrasound-guided renal biopsy in supine antero-lateral position: a new approach for obese and non-obese patients. Nephrol Dial Transplant 2008; 23:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/41\">",
"      Wiseman DA, Hawkins R, Numerow LM, Taub KJ. Percutaneous renal biopsy utilizing real time, ultrasonic guidance and a semiautomated biopsy device. Kidney Int 1990; 38:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/42\">",
"      Maya ID, Maddela P, Barker J, Allon M. Percutaneous renal biopsy: comparison of blind and real-time ultrasound-guided technique. Semin Dial 2007; 20:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/43\">",
"      Doyle AJ, Gregory MC, Terreros DA. Percutaneous native renal biopsy: comparison of a 1.2-mm spring-driven system with a traditional 2-mm hand-driven system. Am J Kidney Dis 1994; 23:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/44\">",
"      Riehl J, Maigatter S, Kierdorf H, et al. Percutaneous renal biopsy: comparison of manual and automated puncture techniques with native and transplanted kidneys. Nephrol Dial Transplant 1994; 9:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/45\">",
"      Mahoney MC, Racadio JM, Merhar GL, First MR. Safety and efficacy of kidney transplant biopsy: Tru-Cut needle vs sonographically guided Biopty gun. AJR Am J Roentgenol 1993; 160:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/46\">",
"      Kim D, Kim H, Shin G, et al. A randomized, prospective, comparative study of manual and automated renal biopsies. Am J Kidney Dis 1998; 32:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/47\">",
"      Burstein DM, Korbet SM, Schwartz MM. The use of the automatic core biopsy system in percutaneous renal biopsies: a comparative study. Am J Kidney Dis 1993; 22:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/48\">",
"      Feneberg R, Schaefer F, Zieger B, et al. Percutaneous renal biopsy in children: a 27-year experience. Nephron 1998; 79:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/49\">",
"      T&oslash;ndel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol 2012; 7:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/50\">",
"      Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 2012; 60:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/51\">",
"      Nicholson ML, Wheatley TJ, Doughman TM, et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int 2000; 58:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/52\">",
"      Pasquariello A, Innocenti M, Batini V, et al. Theoretical calculation of optimal depth in the percutaneous native kidney biopsy to drastically reduce bleeding complications and sample inadequacy for histopathological diagnosis. Nephrol Dial Transplant 2007; 22:3516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/53\">",
"      Katopodis KP, Katsios CG, Koliousi EL, et al. Life-threatening hemorrhage from abdominal aorta following a percutaneous renal biopsy. Clin Nephrol 2006; 65:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/54\">",
"      Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 2005; 9:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/55\">",
"      Soares SM, Fervenza FC, Lager DJ, et al. Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. Am J Kidney Dis 2008; 52:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/56\">",
"      Fish R, Pinney J, Jain P, et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010; 5:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/57\">",
"      Manno C, Bonifati C, Torres DD, et al. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis 2011; 57:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/58\">",
"      Whittier WL. Percutaneous kidney biopsy: \"the needle and the damage done\"? Am J Kidney Dis 2011; 57:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/59\">",
"      Harrison KL, Nghiem HV, Coldwell DM, Davis CL. Renal dysfunction due to an arteriovenous fistula in a transplant recipient. J Am Soc Nephrol 1994; 5:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/60\">",
"      McCune TR, Stone WJ, Breyer JA. Page kidney: case report and review of the literature. Am J Kidney Dis 1991; 18:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/61\">",
"      Bakri RS, Prime M, Haydar A, et al. Three 'Pages' in a chapter of accidents. Nephrol Dial Transplant 2003; 18:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/62\">",
"      Patel TV, Goes N. Page kidney. Kidney Int 2007; 72:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/63\">",
"      Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years' experience. Clin Nephrol 1992; 38:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/64\">",
"      Renal Physicians Association. RPA position on optimal length of observation after percutaneous renal biopsy. Clin Nephrol 2001; 56:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/65\">",
"      Hergesell O, Felten H, Andrassy K, et al. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant 1998; 13:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/66\">",
"      Khajehdehi P, Junaid SM, Salinas-Madrigal L, et al. Percutaneous renal biopsy in the 1990s: safety, value, and implications for early hospital discharge. Am J Kidney Dis 1999; 34:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/67\">",
"      Chodak GW, Gill WB, Wald V, Spargo B. Diagnosis of renal parenchymal diseases by a modified open kidney biopsy technique. Kidney Int 1983; 24:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/68\">",
"      Farrugia, E, Larson, TS. Open renal biopsy: Indications and complications (abstract). J Am Soc Nephrol 1992; 3:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/69\">",
"      Conlon PJ, Kovalik E, Schwab SJ. Percutaneous renal biopsy of ventilated intensive care unit patients. Clin Nephrol 1995; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/70\">",
"      Gimenez LF, Micali S, Chen RN, et al. Laparoscopic renal biopsy. Kidney Int 1998; 54:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/71\">",
"      Gupta M, Haluck RS, Yang HC, et al. Laparoscopic-assisted renal biopsy: an alternative to open approach. Am J Kidney Dis 2000; 36:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/72\">",
"      Anas CM, Hattori R, Morita Y, et al. Efficiency of laparoscopic-assisted renal biopsy. Clin Nephrol 2008; 70:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/73\">",
"      Mal F, Meyrier A, Callard P, et al. The diagnostic yield of transjugular renal biopsy. Experience in 200 cases. Kidney Int 1992; 41:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/74\">",
"      Stiles KP, Yuan CM, Chung EM, et al. Renal biopsy in high-risk patients with medical diseases of the kidney. Am J Kidney Dis 2000; 36:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/75\">",
"      Abbott KC, Musio FM, Chung EM, et al. Transjugular renal biopsy in high-risk patients: an American case series. BMC Nephrol 2002; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/76\">",
"      Meyrier A. Transjugular renal biopsy. Update on hepato-renal needlework. Nephrol Dial Transplant 2005; 20:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/77\">",
"      Cluzel P, Martinez F, Bellin MF, et al. Transjugular versus percutaneous renal biopsy for the diagnosis of parenchymal disease: comparison of sampling effectiveness and complications. Radiology 2000; 215:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/78\">",
"      Thompson BC, Kingdon E, Johnston M, et al. Transjugular kidney biopsy. Am J Kidney Dis 2004; 43:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/79\">",
"      Misra S, Gyamlani G, Swaminathan S, et al. Safety and diagnostic yield of transjugular renal biopsy. J Vasc Interv Radiol 2008; 19:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/80\">",
"      Sam R, Leehey DJ, Picken MM, et al. Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 2001; 37:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/81\">",
"      Sam R, Ing TS. Transjugular renal biopsy: when to do it and when not to? Int J Artif Organs 2001; 24:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/82\">",
"      Sam R, Chebrolu SB, Reyes CV, et al. Transjugular renal biopsy in an unconscious patient maintained on mechanical ventilation. Clin Nephrol 2003; 60:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/83\">",
"      Fine DM, Arepally A, Hofmann LV, et al. Diagnostic utility and safety of transjugular kidney biopsy in the obese patient. Nephrol Dial Transplant 2004; 19:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/11/21690/abstract/84\">",
"      Ahmed MS, Patel A, Borge MA, et al. Simultaneous transjugular renal biopsy and hemodialysis catheter placement in patients with ARF. Am J Kidney Dis 2004; 44:429.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3067 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21690=[""].join("\n");
var outline_f21_11_21690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS AND WHEN BIOPSY MAY NOT BE NECESSARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Isolated glomerular hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Isolated nonnephrotic proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute nephritic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unexplained acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREBIOPSY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RELATIVE CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patients on chronic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Solitary native kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTPROCEDURE OBSERVATION AND TIMING OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONPERCUTANEOUS RENAL BIOPSY TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Open renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laparoscopic renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Transjugular renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3067|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/50/16175\" title=\"diagnostic image 1\">",
"      Renal hematoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/35/10800\" title=\"diagnostic image 2\">",
"      AV fistula after renal bx Angio",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/2/17445?source=related_link\">",
"      Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=related_link\">",
"      Indications for renal biopsy in patients with lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/62/12257?source=related_link\">",
"      Patient information: IgA nephropathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=related_link\">",
"      Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=related_link\">",
"      Patient information: The nephrotic syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=related_link\">",
"      Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=related_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_11_21691="Drugs causing constipation";
var content_f21_11_21691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs associated with constipation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anticholinergics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antispasmodics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cation-containing agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aluminum (antacids, sucralfate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurally active agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opiates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihypertensives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ganglionic blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vinca alkaloids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5HT3 antagonists",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21691=[""].join("\n");
var outline_f21_11_21691=null;
var title_f21_11_21692="Tamoxifen toxicities NSABP P1";
var content_f21_11_21692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxicities of tamoxifen for patients at high risk of breast cancer in NSABP P-01",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Adverse event",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Annual",
"rate per 1000 women",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        RR (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Placebo",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Tamoxifen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        &le;49 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;50 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &le;49 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;50 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &le;49 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        &ge;50 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular accident",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        0.57",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        1.13 (0.39-3.36)",
"       </td>",
"       <td>",
"        1.47 (0.97-2.22)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient ischemic attack",
"       </td>",
"       <td>",
"        0.44",
"       </td>",
"       <td>",
"        1.10",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1.09",
"       </td>",
"       <td>",
"        0.57 (0.12-2.25)",
"       </td>",
"       <td>",
"        0.99 (0.56-1.76)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"       <td>",
"        0.13",
"       </td>",
"       <td>",
"        0.44",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.96",
"       </td>",
"       <td>",
"        2.01 (0.29-22.19)",
"       </td>",
"       <td>",
"        2.16 (1.02-4.89)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep vein thrombosis",
"       </td>",
"       <td>",
"        0.76",
"       </td>",
"       <td>",
"        0.89",
"       </td>",
"       <td>",
"        1.01",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"       <td>",
"        1.34 (0.59-3.10)",
"       </td>",
"       <td>",
"        1.49 (0.84-2.68)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasive endometrial cancer",
"       </td>",
"       <td>",
"        0.82",
"       </td>",
"       <td>",
"        0.58",
"       </td>",
"       <td>",
"        1.16",
"       </td>",
"       <td>",
"        3.08",
"       </td>",
"       <td>",
"        1.42 (0.55-3.81)",
"       </td>",
"       <td>",
"        5.33 (2.47-13.17)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RR: risk ratio for women in the tamoxifen group relative to women in the placebo group; CI: confidence interval.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fisher B, et al. J Natl Cancer Inst 2005; 97:1658.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21692=[""].join("\n");
var outline_f21_11_21692=null;
var title_f21_11_21693="Buffering by phosphate";
var content_f21_11_21693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    General principle of buffering",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 245px; height: 186px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Titration curve of 1 liter of a 20 mmol/L NaH2PO4, Na2HPO4 solution. Initially, the concentration of HPO4(2-) equals that of H2PO4- at 10 mmol/L, and the concentration of H+ equals 160 nanomol/L (pH equals 6.80). The different points represent the effects on the pH of the solution of the addition of a strong acid or base. Maximum buffering, in which large quantities of acid or base can be added with relatively little change in pH, occurs within 1 pH unit of the pK of 6.80.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Woodbury, JW, Physiology and Biophysics, 20th ed, Ruch, TC, Patton, HC (Eds), Saunders, Philadelphia, 1974.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21693=[""].join("\n");
var outline_f21_11_21693=null;
var title_f21_11_21694="Chemo dose modify liver disease";
var content_f21_11_21694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cytotoxic chemotherapy dose modification in patients with preexisting liver disease*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"     </tbody>",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bilirubin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aminotransferases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent dose administered",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ref",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bortezomib",
"       </td>",
"       <td>",
"        &gt;1.5 x ULN",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Reduced starting dose (0.7 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        3.1 to 5 mg/dL",
"       </td>",
"       <td>",
"        AST &ge;180 IU/L",
"       </td>",
"       <td>",
"        75 percent",
"       </td>",
"       <td class=\"centered\" rowspan=\"2\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cabazitaxel",
"       </td>",
"       <td>",
"        &gt;ULN",
"       </td>",
"       <td>",
"        AST/ALT &ge;1.5 x ULN",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cytarabine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        50 percent; subsequent increase by monitoring toxicity",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dactinomycin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        50 percent; subsequent increase by monitoring toxicity",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Daunorubicin",
"       </td>",
"       <td>",
"        1.2 to 3 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        75 percent",
"       </td>",
"       <td class=\"centered\" rowspan=\"3\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 5 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Docetaxel",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        See text",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Doxorubicin",
"       </td>",
"       <td>",
"        1.2 to 3 mg/dL",
"       </td>",
"       <td>",
"        ALT or AST &gt;3 x ULN",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td class=\"centered\" rowspan=\"3\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 5 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Epirubicin",
"       </td>",
"       <td>",
"        1.2 to 3 mg/dL",
"       </td>",
"       <td>",
"        2 to 4 x ULN",
"       </td>",
"       <td>",
"        75 percent",
"       </td>",
"       <td class=\"centered\" rowspan=\"2\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;3 mg/dL",
"       </td>",
"       <td>",
"        &gt;4 x ULN",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Eribulin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        See text",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        1.5 to 3 mg/dL",
"       </td>",
"       <td>",
"        AST &gt;3 x ULN",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        FU",
"       </td>",
"       <td>",
"        &gt;5 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Gemcitabine",
"       </td>",
"       <td>",
"        &gt;1.6 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        80 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ifosfamide",
"       </td>",
"       <td>",
"        &gt;3 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"       <td class=\"centered\">",
"        [1,2]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Irinotecan",
"       </td>",
"       <td>",
"        1.5 to 3 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        75 percent",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Ixabepilone monotherapy",
"       </td>",
"       <td>",
"        &le;1 x ULN",
"       </td>",
"       <td>",
"        AST and ALT &le;2.5 x ULN",
"       </td>",
"       <td>",
"        Initial dose (40 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"centered\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &le;1 x ULN",
"       </td>",
"       <td>",
"        AST and ALT &le;10 x ULN",
"       </td>",
"       <td>",
"        Initial dose (32 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;1.5 x ULN to &le;3 x ULN",
"       </td>",
"       <td>",
"        AST and ALT &le;10 x ULN",
"       </td>",
"       <td>",
"        Initial dose (20-30 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;3 x ULN",
"       </td>",
"       <td>",
"        &gt;10 x ULN",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ixabepilone plus capecitabine",
"       </td>",
"       <td>",
"        &ge;2.5 x ULN",
"       </td>",
"       <td>",
"        Above ULN",
"       </td>",
"       <td>",
"        Omit",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Paclitaxel",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        See text",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Procarbazine",
"       </td>",
"       <td>",
"        &gt;5 mg/dL",
"       </td>",
"       <td>",
"        ALT or AST &gt;3 x ULN",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td class=\"centered\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vincristine, vinblastine",
"       </td>",
"       <td>",
"        &gt;3 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td class=\"centered\">",
"        [3]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Vinorelbine",
"       </td>",
"       <td>",
"        2.1 to 3 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td class=\"centered\" rowspan=\"2\">",
"        [1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;3 mg/dL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Vorinostat",
"       </td>",
"       <td>",
"        &gt;1 to 3 x ULN",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Reduce initial dose",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;3 x ULN",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FU: fluorouracil; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal.",
"     <br/>",
"     * Not an inclusive list.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Controversial. Supported by some studies (Venook A. J Clin Oncol 2000; 18:2780), but not others (Teusink A. Ann Pharmacother 2010; 44:750).",
"     <br/>",
"     &Delta; US FDA guidelines; Canadian guidelines recommend avoiding the drug for total bilirubin &ge;1.5 x ULN.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Floyd J, et al. Semin Oncol 2006; 33:50.",
"      </li>",
"      <li>",
"       Falkson G, et al. Invest New Drugs 1992; 10:337.",
"      </li>",
"      <li>",
"       Desai ZR, et al. Cancer Chemother Pharmacol 1982; 8:211.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21694=[""].join("\n");
var outline_f21_11_21694=null;
var title_f21_11_21695="Radiograph nonossifying fibroma";
var content_f21_11_21695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-ossifying fibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A non-ossifying fibroma can usually be diagnosed with confidence from imaging studies alone, and seldom requires either biopsy or operative intervention. The lesion is recognized by its eccentric (cortical) origin, \"polycyclic\" outline, well-formed thin sclerotic wall, and progressive ossification, beginning with the portion of the lesion furthest from the growth plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_11_21695=[""].join("\n");
var outline_f21_11_21695=null;
